












































University of Palermo 
 
Department of Biological Chemical and Pharmaceutical Sciences and Technology 
(STEBICEF) - Faculty of Science 
 
Scientific area code BIO/11 
 
Phd in Cell Biology and Pharmaceutical Technological Sciences (Cellular Biology) 
Fine characterization of immunological mechanisms 
mediated by the major allergens of Parietaria judaica and 
hypoallergenic hybrid, rPjEDcys. 
 
Phd thesis of: 
Dr. Daniela Di Blasi 
Phd Coordinator 
Prof. Maria Carmela Roccheri 
Co-Tutor: 
Dr. Angela Bonura 


















Prof. Maria Antonietta Ragusa 

















XXVI Cycle – A.A. 2015/2016 
 
Index 
Abstract .................................................................................................................................................................... 1 
 
Introduction ............................................................................................................................................................. 2 
1. Immune system ................................................................................................................................................. 2 
1.1. Innate immunity ........................................................................................................................................ 3 
1.2. Adaptive immunity .................................................................................................................................... 5 
1.2.1. B Lymphocytes (B cells) .................................................................................................................... 6 
1.2.2. T Lymphocytes (T cells) ..................................................................................................................... 6 
1.2.2.1. Cytotoxic T Lymphocytes (CTLs) ............................................................................................... 7 
1.2.2.2. T helper cells (Th cells) .............................................................................................................. 7 
1.2.2.3. T regulatory cells (Tregs) ......................................................................................................... 10 
2. Allergy ............................................................................................................................................................ 15 
2.1. Cytokines and allergy ............................................................................................................................. 18 
2.2. Natural Killer (NK) cells and their role in allergy ................................................................................. 19 
2.3. T regulatory cells and their role in allergy ............................................................................................. 20 
3. Allergen-Specific ImmunoTherapy (SIT) ....................................................................................................... 21 
3.1. Immuno deviation during SIT ................................................................................................................. 25 
4. Parietaria judaica (Pj) ................................................................................................................................... 27 
4.1 Parietaria judaica allergens .................................................................................................................... 27 
 
Objective ................................................................................................................................................................. 30 
 
Material and Methods ............................................................................................................................................ 31 
1. Production of recombinant proteins .............................................................................................................. 31 
1.1. Affinity chromatography ......................................................................................................................... 31 
1.2. Dialysis ................................................................................................................................................... 31 
1.3. Second affinity chromatography ............................................................................................................. 32 
1.4. Gel filtration chromatography ................................................................................................................ 32 
1.5. Detoxi-Gel Endotoxin Removing Gel ...................................................................................................... 32 
1.6. Protein quantification assay ................................................................................................................... 33 
1.7. Limulus Amebocyte Lysate test (LAL test) .............................................................................................. 33 
2 Patient selection .............................................................................................................................................. 34 
3. Human Peripheral Blood Mononuclear Cells (PBMC) isolation .................................................................. 34 
4. Flow cytometry ............................................................................................................................................... 35 
5. 5(6)-Carboxyfluorescein Diacetate Succinimidyl Ester (CFDA-SE) staining ............................................... 36 
6. Cytokine Secretion Assay: IL-5, IL-13, IFN- γ and IL-10 .............................................................................. 36 
7. Immunophenotyping of CD4+ CD25++ cells .................................................................................................. 38 
8. Immunophenotyping of CD4+ CD25++ CD127- T regulatory cells ................................................................ 38 
9. Immunophenotyping of CD4+ CD25++ GARP+ and CD4+ CD25++ LAP+ T regulatory cells ....................... 38 
10. Multiparametric analysis of CD4+ CD25++ GARP+ LAP+ T regulatory cells ............................................. 39 
11. Immunophenotyping of CD4+ CD39+ GARP+ and CD4+ CD39+ LAP+ T regulatory cells. ........................ 39 
12. Immunophenotyping of CD4+ CD25++ PD1+ cells ...................................................................................... 39 
13. CD4+CD25++ CD127- Tregs isolation from human PBMC ......................................................................... 39 
14. TRIzol RNA extraction ................................................................................................................................. 41 
15. cDNA synthesis ............................................................................................................................................. 42 
16. Real Time-PCR ............................................................................................................................................. 43 




Results .................................................................................................................................................................... 45 
1. Production of recombinant proteins: rPar j1, rPar j 2 and rPjEDcys .......................................................... 45 
2. Human PBMC proliferation assay: innate and adaptive immune response to Parietaria major allergens 
and the hypoallergenic derivate ......................................................................................................................... 47 
2.1 Cytofluorimetric analysis on CD4+CFSE+ cells ...................................................................................... 48 
2.2 Cytofluorimetric analysis on CD8+CFSE+ cells ...................................................................................... 49 
2.3 Cytofluorimetric analysis on CD16+CFSE+ cells .................................................................................... 51 
2.4 Cytofluorimetric analysis on CD56+CFSE+ cells .................................................................................... 52 
3. IL-5, IL-13, IL-10 and IFN-γ cytokine secretion assay after PBMC stimulation with wild type allergens and 
rPjEDcys ............................................................................................................................................................ 54 
4. Modulation of CD25 expression on CD4+ cells in response to Parietaria major allergens and rPjEDcys .. 62 
5. Study of allergen-specific CD4+ CD25++ CD127- Tregs after PBMC stimulation with Parietaria major 
allergens and hypoallergenic hybrid .................................................................................................................. 65 
6. Magnetic separation of CD4+ CD25++ CD127- Tregs after stimulation with Parietaria major allergens and 
hypoallergenic hybrid ........................................................................................................................................ 69 
7. Molecular characterization of allergen-specific CD4+ CD25++ CD127- T Regulatory Cell ......................... 76 
8. Analysis of GARP and LAP expression on CD4+CD25++ cells in response to Parietaria major allergens 
and rPjEDcys ..................................................................................................................................................... 79 
9. Study of GARP and LAP co-expression on CD4+CD25++ cells after PBMC stimulation with the mixture of 
wild type allergens and the hypoallergenic derivate ......................................................................................... 87 
10. Analysis of CD39 expression on CD4+ cells in response to Parietaria major allergens and rPjEDcys ..... 89 
11. Evaluation of putative cross-talk between two suppressive pathways of human Treg cells ........................ 93 
12. Analysis of PD1 expression on CD4+ CD25++ cells in response to Parietaria major allergens and 
rPjEDcys .......................................................................................................................................................... 103 
 
Discussion ............................................................................................................................................................ 107 
 
Conclusion ........................................................................................................................................................... 113 
 
References ............................................................................................................................................................ 113 
 














Allergy is a hypersensitivity disease IgE-mediated, affecting more than 30% of the population living 
in the industrialized countries. The symptoms of allergic reactions can be transiently ameliorated 
pharmacologically, but the only curative treatment of allergies is Allergen-Specific Immunotherapy 
(SIT). Recombinant hypoallergenic derivatives with reduced allergenic activity have been engineered 
to reduce side effects during SIT. Parietaria judaica (Pj) pollen contains two major allergens 
belonging to the family of non specific-Lipid Transfer Proteins (ns-LTP): Par j 1 and Par j 2. The 
allergens Par j 1 and Par j 2 are recognized in approximately 95% of allergic patients. By means of 
DNA recombinant technology, a hybrid hypoallergenic (PjEDcys), expressing disulphide bond 
variants of Par j 1 and Par j 2, has been generated. The aim of this research project is to study the 
immunological mechanisms activated by the major allergens of Parietaria judaica, rPar j 1 and rPar j 
2, and the hypoallergenic hybrid rPjEDcys. Moreover, the project I am involved in is trying to 
address the question whether this engineered hypoallergenic derivative can be a potential product for 
safer Allergen Specific Immunotherapy. In vitro analysis suggested that rPjEDcys has a reduced 
allergenity and maintains T cells reactivity. In particular we showed that PBMC of Pj allergic 
patients stimulated in vitro with the hybrid and the wild-type recombinant allergens scored a 
percentage of proliferating CD4+ cells higher than unstimulated samples. We also demonstrate that 
components of innate immune system (CD56+ cells) proliferate in response to wild-type allergens and 
rPjEDcys. Furthermore, cytokine secretion assays on CD4+ cells demonstrated that rPjEDcys induces 
a lower the secretion of two Th2 cytokines that are critical in the development of allergy such as IL-5 
and IL-13 compared to wild-type allergens. Furthermore we observed the induction of a Treg cell 
subset (defined as CD4+ CD25++ CD127-) in response to rPjEDcys and the wild-type allergens. 
However, the number of these Treg cells and the intensity of CD25 expression is higher in response to 
hypoallergen hybrid than Parietaria major allergens. We also characterized these cells at molecular 
level by REAL-TIME PCR. Moreover, we addressed the kinetic of functional surface marker 
expression, such as GARP (Glycoprotein A Repetitions Predominant), LAP (Latency-Associated 
Peptide) CD39 and PD1 on CD4+ cells. Our analyses demonstrated that rPjEDcys induces a number 
of GARP-LAP-CD39 co-expressing cells and CD4+CD25++PD1+ higher than wild-type recombinant 
allergens. These results suggest that rPjEDcys represents a useful approach for immunotherapy of 





1. Immune system 
The immune system is a complex interactive network of cells, tissues and organs that work 
together to defend the body against attacks by “foreign” insults while keeping a state of tolerance 
to self and innocuous non-self antigens. Structurally, the immune system is a collection of cells, 
molecules, tissue, organs and circulatory systems. Immune system cells are produced and mature 
in specialised areas of the body called primary lymphoid organs such as the thymus or bone 
marrow. They are transported via the cardiovascular and lymphatic circulatory systems to 
peripheral tissues or specialised secondary lymphoid organs such as the lymph nodes or spleen. 
Although scientists have learned much about the immune system, it is highly complex and 
continuous studies have to be performed to understand how the human immune system targets 
invading microbes, infected cells and tumors while ignoring healthy tissues. Our environment 
contains a large amount of organisms and substances that damage the host through a very broad 
selection of pathogenic mechanisms. Therefore human immune system uses a complex array of 
protective mechanisms to locate and eliminate these organisms and environment substances from 
the body and maintain the body in a healthy state for many years. 
A general feature of the human immune system is the ability to detect structural features of the 
pathogen, toxin, tumor cells or allergenic structure (non self) that mark it as distinct from body’s 
own cells (self). The body’s immune defenses normally coexist peacefully with cells that carry 
distinctive “self” marker molecules. However, when host immune cells encounter cells or 
organisms carrying foreign markers they attack [1-2].  
Once immune cells recognize the enemies, they become activated and begin to produce and 
secreted cytokines, molecules that mediate and regulate their own growth and cell behaviour, and 
chemokines, molecules that stimulate cell movement and recruit other immune cells into the 
infection site. These cells can produce and release a large amount of chemical mediators and 
activate other cells involved in immune response in order to attack organisms and substances that 
invade body systems and cause disease [1]. These events allow us to maintain the homeostasis of 
the body.  
This view of the immune system describe it as a multilevel dynamic system of cells, molecules, 
tissue, organs and circulatory systems that protects organisms from infection with a different 
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1.1. Innate immunity 
Innate immunity is an evolutionarily ancient part of the host defense mechanisms and provides the 
first line of defense against invading bacteria [1].  
The innate immune system includes physical, chemical and cellular barriers. The main physical 
barriers are skin and mucous membranes. Chemical barriers include specialized soluble molecules 
that have antimicrobial activity, these represent one of the most ancient forms of defense against 
infection; the most noteworthy antibacterial substance is the enzyme lysozyme. Innate responses 
frequently involve complement, acute-phase proteins, and cytokines. The molecules collectively 
referred to as acute-phase proteins enhance resistance to infection and promote the repair of 
damaged tissue. Cytokines act as messengers both within the immune system and between the 
immune system and other systems of the body, generating an integrated network that is involved 
in the regulation of immune responses.  
Innate immune cells include populations of white blood cells such as circulating Dendritic Cells 
(DCs), neutrophiles, Natural Killer (NK) cells, Natural Killer T (NKT) cells, monocytes, 
eosinophiles and basophiles, along with tissue-resident mast cells and macrophages [1-3]. 
The cellular response to a microbial agent of infection that overcomes the initial barriers of skin 
Fig 1. Innate and Adaptive Immunity: the mechanisms of innate immunity provide the initial defense against 
infections.  Adaptive immune responses develop later and consist of activation of lymphocytes.  The kinetics of 




and mucous membranes is rapid, typically initiating within minutes of invasion. Innate immune 
cells accomplish general pattern recognition by using a variety of Pattern Recognition Receptors 
(PRRs) that can be expressed on the cell surface, in intracellular compartments, or secreted into 
the bloodstream and tissue fluids and recognized microb-specific molecule called Pathogen-
Associated Molecular Patterns (PAMPs) [4-6]. The innate immune system consists of all the 
immune defenses that lack immunologic memory, their response does not change, regardless of 
the type of pathogen involved.. Thus, a characteristic of innate responses is that they remain 
unchanged however often the antigen is encountered.  
NK cells are a type of cytotoxic lymphocyte critical to the innate immune system. NK cells are 
known to differentiate from the common lymphoid progenitor-generating B and T lymphocytes 
and mature in the bone marrow, lymph nodes, spleen, tonsils, and thymus, where they then enter 
into the circulation [1-2]. These cells can be distinguished from other lymphocytes with the lack of 
the T cell receptor and surface immunoglobulin, but these cells express many NK cell-specific 
surface molecules. Human NK cells express structurally and functionally two distinct families of 
Major Histocompatibility Complex (MHC) class I receptors: Killer cell Immunoglobulin (Ig)-like 
Receptors (KIR) and lectin-like receptors. These cells have the ability to both lyse target cells and 
also provide an early source of immunoregulatory cytokine [7-8]. Human NK cells comprise 15% 
of all lymphocytes and are defined phenotypically by their expression of CD56, an isoform of the 
human neural-cell adhesion molecule with unknown function on human NK cells and lack of 
expression of CD3, T cell co-receptor and CD16, the low-affinity Fcγ receptor III (FcγRIII). 
However, two distinct populations of human NK cells could be identified, based on their cell-
surface density of CD56 and CD16. The majority (90%) of human NK cells have low-density 
expression of CD56 and express high levels of CD16 (NK cells CD56dimCD16bright); whereas 10% 
of NK cells are CD56brightCD16dim/−. Functional studies of these subsets by Lanier and colleagues 
revealed that resting CD56dimCD16bright cells are naturally more cytotoxic than CD56bright CD16dim/- 
NK cells. Consistent with these cytotoxic differences, CD56dim CD16brightNK cells have a major 
number of cytoplasmic granules containing proteins such as perforin and proteases (known as 
granzymes) and higher level expression of KIRs than CD56bright CD16dim/- cells.  
By contrast CD56brightCD16dim/- NK cells have low level expression of KIRs but have the capacity 
to produce higher levels of immunoregulatory cytokines, such as interferon (IFN)-γ, Tumour 
Necrosis Factor (TNF)-α, Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) and IL-















1.2. Adaptive immunity 
Innate immunity, alone, may not be sufficient to protect a host against an invading pathogen or to 
prevent disease from occurring. However, if innate immunity fails, the pathogen may yet be 
detected and attacked by the mechanisms of adaptive immunity. The innate and adaptive immune 
responses synergistically act as protection against invading organisms, but they differ in a number 
of ways. The adaptive immune system shows delayed responses to pathogens.  
The two main cell populations of the adaptive immune system are T and B lymphocytes (T and B 
cells), which recognize a high diversity of antigens. The adaptive immune is also called specific 
immune response and consists of antibody responses and cell-mediated responses, which are 
carried out by B and T cells, respectively. The B and T cell receptors are random products of 
somatic gene rearrangement during maturation. The genes encoding these receptors are assembled 
in random product by the activity of enzymes called RAG-1 and RAG-2 (Recombination 
Activation Gene). Defence against extracellular microbes and microbial toxin is mediated by B 
cells, instead intracellular microorganisms are detected by T lymphocytes via cell-mediated 
immune responses [1-2].  
 
 
Fig. 2. Schema of human natural killer (NK)-cell subsets: (a) CD56bright CD16dim/- NK cells produce high levels 
of cytokines following stimulation. This subset has low-density expression of CD16 and low natural cytotoxicity 
and antibody-dependent cellular cytotoxicity (ADCC). Therefore, this NK-cell subset expresses a number of 
cytokine and chemokine receptors constitutively. (b) CD56dim NK cells produce low levels of NK-derived 
cytokines but are potent mediators of ADCC, LAK activity and natural cytotoxicity, and have a more granular 
morphology than CD56bright CD16dim/- NK cells. The CD56dim CD16 bright NK-cell subset has high-level expression 
of KIRs [7]. 
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1.2.1. B Lymphocytes (B cells) 
B cells are a subset of lymphocytes involved in the production of antibodies that are released in 
blood plasma and lymph, where they bind specifically to foreign antigens. 
B cells arise from hemopoietic stem cells in the bone marrow, where B cells pass through several 
distinctive developmental stages, during which they acquire their antigen specificity. Upon the 
first exposure to a microbe or an antigen and the recognition of foreign antigens through the B Cell 
Receptor (BCR), the naïve B-lymphocytes are activated and differentiated into antibody-producing 
plasma cells and memory cells. When the same antigen reenters the body, the circulating 
antibodies provide immediate protection against infection.  
The antibodies secreted by plasma cells can be grouped into different antibody classes or isotypes. 
There are five different antibody isotypes known as IgA, IgD, IgE, IgG and IgM that perform 
different roles. [1-2] 
 
1.2.2. T Lymphocytes (T cells) 
T cells, or T lymphocytes, are a subset of lymphocytes defined by their development in the 
thymus, where they develop to recognize cell surface molecules presenting foreign antigens 
(antigen-MHC).  MHC molecules are encoded by the Major Histocompatibility Complex (MHC) 
genes and determine histocompatibility. All T cell express CD3 antigen and an unique T Cell 
Receptor (TCR), but they differ for CD4 and CD8 expression, which act as coreceptor. The initial 
step of differentiation of the naïve cells is the antigenic stimulation as a result of interaction of 
TCR and CD4+ or CD8+ with antigen-MHC class II or MHC class I complex respectively, 
presented on professional antigen presenting cells (APCs). 
Naïve T cells express CD28, the receptor for the peripheral membrane proteins (type B7) found on 
APCs that provide co-stimulatory signals (in addition to the TCR) required for T cell activation 
and survival. Blockade of CD28 is effective in stopping T cell activation, a mechanism that the 
immune system uses to down-regulate T cell activation. Association of the TCR of a naïve T cell 
with MHC:antigen complex without CD28:B7 interaction results in a T cell that is anergic.  
T cells contribute to immune defenses in two major ways. Some T cells (CD4+ T cells) direct and 
regulate immune responses, whereas others T (CD8+ T cells) cells attack directly infected or 




1.2.2.1. Cytotoxic T Lymphocytes (CTLs)  
The CD8+ T cells are Cytotoxic T Lymphocytes (CTLs) which attack directly or kill infected cells 
expressing foreign antigen fragments in the context of their class I molecules. Moreover, CTLs are 
useful for attacking tumor cells. CD8+ T cells use multiple mechanisms to kill tumor or infected 
cells; they release two preformed cytotoxic proteins, granzymes and perforin, and secrete 
cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor (TNF). Both perforin and 
granzymes are required for effective cell killing. The granzymes are cellular proteases, they are 
formed in the CD8+ T cell only after antigen-specific activation of the cell and trigger apoptosis in 
the target cell, activating an enzyme cascade that induces the DNA degradation. Instead, the 
perforines make pores on cell surface through which the granzymes can move into the target cell. 
The cytokines expressed by CD8+ T cells (IFN-γ and TNF-α) are also important because they 
mediate many antitumor effects. IFN-γ is well known for its antiangiogenic properties. 
Experimental evidences suggest that IFN-γ and TNF-α released from CTL are key effector 
molecules for the eradication of tumor by the destruction of tumor stroma [9]. 
 
1.2.2.2. T helper cells (Th cells) 
The CD4+ T cells are called T helper cells; these play an important role in the regulation of the 
immune system, coordinating the activity of the immune response. As suggested by their name, Th 
cells modulate the function of B cells by inducing antibody secretion and isotype switching. Th 
cells are not able to directly kill infected cells, but they play an essential role also in the regulation 
of CD8+ cytotoxic T cells. 
The helper T cells recognize foreign antigen in the context of their MHC class II molecules. When 
an antigen-presenting cell (APC) activates a naïve helper T cell in a peripheral lymphoid tissue, 
this T cell can differentiate into effector T cell subset. Mosmann and Coffman originally classified 
CD4+ T lymphocytes into Th1 and Th2 subsets [9-10].  
They showed that T naïve cells (T helper type 0, Th0) could differentiate into Th1 or Th2 effector 
cells; many factors could influence Th1/Th2 differentiation. Among these ones there are the dose 
and the nature of antigens and the interaction with different APCs but the polarization process is 
driven mainly by cytokines produced by APCs. IL-12 and IL-4 are defined as the critical cytokines 
initiating the downstream signaling cascade to induce naïve T CD4+ cells to differentiate into Th1 
or Th2 cells [11-12]. IL-12 appears to induce IFN-γ, a key factor in Th1 polarization from Th0. 
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IFN-γ acts to up-regulate the master regulator for Th1 differentiation, T-box transcription factor 
(T-bet) showing a positive feedback loop for Th1 differentiation. On the contrary, IL-4 and IL-2 
are critical for Th2 differentiation and up-regulate the expression of the master regulator GATA-
binding protein (GATA3). GATA3 is indispensable for Th2 differentiation and Th2 cytokine 
production. It is also essential for inhibition of Th1 differentiation and IFN-γ production [13-14]. 
These two types of effector helper T cells (Th1 and Th2) are functionally distinct, can be 
characterized by the cytokines they secrete and play different immune responses. 
If Th0 cells differentiate into a Th1 cells, they will secrete IFN-γ and TNF-α. Under physiological 
conditions, Th1 pathway primarily acts in the defense against intracellular pathogens. IFN-γ is the 
most characteristic cytokine produced by activated Th1. It shows a multitude of functions; for 
example it promotes phagocytosis and elimination of intracellular pathogens by upregulation of 
the expression of high affinity IgG Fc region receptor (FcγRI).  Activation of the FcγR via antigen 
containing immune complexes lead to the pathogen phagocytosis and can lead to the generation of 
reactive oxygen species which in turn actively participate in phagocytosis.  
Th1 cells may also stimulate B cells to secrete specific subclasses of IgG antibodies that can coat 
extracellular microbes and activate the complement system. Th1 immune response is essential in 
the clearance of intracellular pathogens but if they are over activated under pathological conditions 
they could promote autoimmune diseases. In fact, exceeding Th1 responses have been found to be 
associated with autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis and type 1 
diabetes. 
Otherwise, Th2 cells mediate host defense against extracellular parasites. Moreover, Th2 cells are 
well known for their involvement in allergies, these cells are in fact the main causes of allergic 
inflammatory diseases and asthma [11-12, 15].  
Th2 responses are associated with a high production of a large range of cytokines, including IL-4, 
IL-5, IL-9 and IL-13. Th2 cytokines exert their effects on many cell types in the organism. In fact, 
Th2 cells are able to stimulate and recruit specialized subsets of immune cells, such as 
eosinophiles, basophiles, neutrophiles and mast cells, towards the site of infection or in response to 
allergens. Th2 cytokines also induce Igε gene transcription in B cells, which results in 
subsequently class switching towards the IgE isotype, a critical mediator of allergy. 
Although, initially, immunologists believed that there were fundamentally 2 types of CD4+ T cells, 
Th1 and Th2, the repertoire of effector CD4+ T cell subsets has recently expanded to include 





















The differentiation of the different lineages depends on the complex network of specific cytokine 
signaling and transcription factors followed by epigenetic modifications. Th17 cells secrete a 
characteristic profile of cytokines including IL-17A, IL-17F and IL-22. The natural role of Th17 
cells in the immune system is to protect the organism from extracellular bacteria and fungal 
infections but an uncontrolled or inappropriate Th17 activation has been linked to several 
autoimmune pathologies such as arthritis, multiple sclerosis, psoriasis and lupus [16-18].  
The second important effector T CD4+ cells named T regulatory cells have been identified in 1970 
by Gershon and Kondo. These cells showed a distinct suppressive activity and for this reason they 
were initially named suppressive cells. Our immune system consists of a complex network of 
regulatory response that maintain the immune homeostasis. Tregs are the main cells involved in 
the regulation of both innate and adaptive immune response. This feature makes these cells 
important in maintaining peripheral immune tolerance. 
Tregs are CD4+CD25++ and have suppressive effects that are essential for maintaining self-
tolerance and controlling pathological immune responses, in order to control autoantigen reactions 
such as those which cause autoimmunity diseases. The generation of Tregs constitutes an essential 
mechanism in the establishment and maintenance of peripheral tolerance [19-21]. 
Fig. 3 The major subclasses of effector helper T cells: these cells are functionally distinct and can be 
distinguished by the cytokines they secrete [11]. 
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1.2.2.3. T regulatory cells (Tregs) 
As mentioned before, Tregs are a heterogeneous group of CD4+ T cells, therefore, during the Third 
International Conference on Regulatory T Cells and Th Subsets and Clinical Application in 
Human Diseases held in Shanghai in 2012, several recommendations were developed to simplify 
the nomenclature of Tregs. 
Tregs can be divided based on their origin into: naturally occurring Treg cells, which develop in 
the thymus (tTregs or nTregs); and induced Treg cells that develop in the periphery (pTregs or 
iTregs) [22].  
In addition to their origin, Tregs could be divided based on their surface markers and their 
mechanism of action.  
Naturally occurring regulatory T cells are the best-characterized Tregs and constitute a distinct cell 
lineage in the periphery, being 5%–10% of the total peripheral CD4+ T cells. Although there is no 
cell surface marker that uniquely identifies tTregs, there are cell surface proteins that are 
preferentially expressed on tTregs. The cells constitutively express a high level of CD25 [high 
affinity interleukin-2 receptor, alpha chain (IL-2Rα)], however this receptor is not only expressed 
by Treg cells but by all activated T cells. In contrast, CD127 [interleukin-7 receptor, alpha chain 
(IL-7Rα)] is absent in Treg and although it is down regulated in activated effector T cells,, this 
marker allows to distinguish Tregs from effector T cells. Besides the expression of CD25 and the 
absence of CD127, these cells constitutively express other several activation markers including the 
glucocorticoid-induced tumor-necrosis factor (TNF) receptor-related protein (GITR), L-selectin 
[CD62 ligand (CD62L)], cytotoxic T lymphocyte-associated antigen 4 (CTLA-4 or CD152) and 
OX40 (CD134) [23-26].  
Even so, it has been observed that none of these markers exclusively identifies Tregs since they 
can also be expressed in various degrees on activated effector T cells. tTregs are characterized by 
the expression of the transcription factor Fork head Box P3 (FoxP3 or scurfin) is key transcription 
factor indispensable for Treg development in the thymus [26]. 
In mice, CD4+ Tregs are a homogenous population, in which all CD4+ and CD25+ cells are Tregs. 
In humans, the Tregs are a heterogeneous population, in which not all CD25+ cells are Tregs. 
Several studies have identified the transcription factor FoxP3 as the “master regulator” of tTreg, in 
which it is constitutively expressed at high levels, but now it is well evident that the tTreg activity 
is not only regulated by FoxP3 expression [26-27]. Previous studies have revealed the specific role 
of FoxP3 in the development and function of natural Tregs. First findings were obtained in a mice 
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model of FoxP3 deficient recombinant mice and the natural mutant scurfy mice, which showed the 
crucial role of FoxP3 in the development of tTreg. Scurfy mice have a frameshift mutation in the 
FoxP3 gene that results in a truncated protein lacking the fork head domain. FoxP3 is sufficient for 
the development and the function of Tregs in mice. In fact, the destruction or spontaneous 
mutation of FoxP3 gene causes the absence of Treg cells in mice and induce the 
lymphoproliferative autoimmune syndrome characterized by multiorgan lymphocytic infiltration 
and uncontrolled cytokine secretion [27-28]. 
The human FoxP3 gene maps on X chromosome and it has been observed that FoxP3 mutation 
leads to autoimmune disease with clinical effect similar to those observed in scurfy mice. This 
syndrome is known as immune dysfunction polyendocrinopathy enteropathy X-linked (IPEX) and 
is a rare recessive disorder showing an X-linked hereditary pattern: only males are affected, 
whereas the carrier mothers are healthy. Patients with IPEX have shown multiorgan lymphocytic 
infiltration and typically develop autoimmune diseases that are related to Tregs deficit [28]. Novel 
findings obtained in mice model revealed that FoxP3 is able to upregulate or down regulate more 
than 700 genes; FoxP3 directly regulates 10% of these [29].  
Not all human Treg cells constitutively express FoxP3. The other type of regulatory T cells, named 
peripherally generated T regulatory (pTreg), can differentiate in the periphery from non-Tregs and 
could acquire FoxP3 expression in response to foreign antigens and show suppressive functions 
similar to tTregs. These cells can be generated under more various conditions, for example they 
can be generated in lamina propria of the intestine in response to microbiota and food allergens, in 
every chronically inflamed tissue or grafts. pTregs development always needs TCR stimulation 
and the cytokines TGF-β and IL-2 [30]. Surely, the existence of different subsets of Treg and lack 
of a define cell surface signature makes it difficult to understand the role of each regulatory cells 
in the regulation of our immune system. 
Different Treg subsets have been identified based on the phenotypic expression of functional 
markers and their suppressive activity. Treg uses many mechanisms to limit the activation of other 
immune cells and ensure an immune tolerance. These include the contact-dependent and 
independent mechanisms that comprise the secretion of immunomodulatory cytokines, the 
metabolic distruption modulation of DCs, and the cytolysis of target cells [31-32].  
The main mechanism by which Treg cells control immune responses is through the secretion of 
high levels of the immunosuppressive cytokines IL-10 and TGF-β. In vivo studies have shown that  




 IL-10, has potent immunomodulatory effect that suppresses effector T cell response in two 
different ways; directly by suppressing IL-2 and INF-γ secretion and T cell proliferation or 
indirectly by inhibiting inflammatory factors and activating tolerogenic pathways [26]. However, 
Treg cells are not the only T cell subset that secretes IL-10; other T cell subsets can express IL-10, 
depending on stimulation and environmental conditions.  
Treg cells show a typical kinetics of IL-10 secretion, they produce high concentrations of IL-10 
early after antigen specific stimulation while IL-10 production by other Th cell clones or 
peripheral blood cells occurs late after stimulation and it is less concentrated [33].  
TGF-β is another important pleiotropic cytokine with immunoregulatory properties, which plays 
an essential role in the maintenance of immunological tolerance. This cytokine has multiple 
suppressive effects on T cells, B cells, macrophages and other immune cells [34].  
Moreover, TGF-β could be found in the latent form associated with Latency-Associated Peptide 
(LAP) on Treg cell surface, but their suppressive mechanism is mediated by TGF-β secretion 
rather than through cell surface-bound TGF-β [35]. Activation of TGF-β is a highly regulated 
process at the post-translational level; TGF-β is synthesized in cells as a pro-TGF-β precursor. 
Following a homodimerization step, pro-TGF-β is cleaved by furin convertase, which forms a 
complex that contains mature TGF-β associated to LAP. The C-terminal homodimer corresponds 
to mature TGF-β, while the N-terminal homodimer is LAP peptide. TGF-β is active only after the 
dissociation from LAP. More recently, an orphan toll-like receptor called Glycoprotein A 
Repetitions Predominant (GARP, or LRRC32) has been identified as a novel marker for Tregs 
involved in regulatory function, in particular associated with TGF- β suppressive mechanism [35]. 
The GARP protein was identified as a cell surface protein of Treg cells. Mutational study by 
Unutmaz et al revealed that deletion of the cytoplasmic portion of GARP did not affect Treg 
phenotype or function; on the contrary the transmembrane region and the extracellular region were 
important in its function infact the depletion of either region abrogated Treg suppressor function. 
Flow cytometry analysis on the cell surface expression of GARP showed the absence of this 
protein on the cell surface of any resting Treg or T conventional cell [36]. Thanks to the discovery 
of GARP more light was given to TGF- β on Treg cell biology.  
Some published data showed that GARP is selectively up-regulated on Tregs after TCR activation, 
this surface molecule has been described as unique activation marker of human Tregs [37]. 
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Instead, FoxP3 and CD25 are costitutively expressed on Tregs and cannot be used to evaluate 
activation status [38].  
GARP mRNA was found expressed at low basal level in other cell types, but GARP protein was 
not expressed, these observation highlight that there is a post-transcriptional regulation of GARP 
[35-36]. GARP expression is selectively restricted to the FoxP3+ cells and this has led to the 
hypothesis that GARP is an effector molecule regulated by FoxP3 expression. Silencing FoxP3 by 
shRNA expression in Tregs showed a reduction of GARP up-regulation. On the contrary reduced 
GARP expression with shRNA in Tregs induced a moderate reduction of suppressive activity but 
did not change FoxP3 expression. These findings highlighted that GARP could have a potential 
contribution into Treg-mediate suppression [37-39].  
Tran et. al. showed that GARP function is to associate with latent transforming growth factor- β 













Metabolic distruption is another strategy used by Tregs to suppress other cells. A primary 
mechanism is the consumption of local IL-2, which they need for survival and proliferation. 
Recent studies on murine model indicated that ATP is implicated in the pathogenesis of allergy by 
triggering the migration of eosinophils and dendritic cells (DCs) and promoting the maturation and 
activation of DCs [41]. Some reports have shown that T regulatory cells express ectoenzyme 
CD39 [Ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1)] and CD73 [ecto-5′-
nucleotidase] and use these enzyme to mediate immunosuppression through the production of 
adenosine. Human Treg cells have been reported to express CD39 on their surface to hydrolyze 
 Fig 4. Model of TGF-ß production by Human Treg cells. Functional association between GARP and LAP 
proteins [45].  
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extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP) into adenosine 
monophosphate (AMP). Thereafter, AMP is processed into immunosuppressive adenosine by the 
CD73 ectoenzyme. This mechanism is important in the immune regulation, in fact the purinergic 
mediators, like ATP and adenosine, are released into the extracellular space and act as positive or 
negative signals modulating the immune responses. ATP induces pro-inflammatory responses, 
such as the release of inflammatory cytokines. On the contrary, adenosine mediates anti-
inflammatory effects by inhibiting activated immune cells in a negative feedback loop.  
The inhibitory effect of adenosine on T cells is mediated by the ability to block T-cell receptor 
signaling due to the binding of adenosine to A2A receptors (the main adenosine receptor) and the 
























Tregs can also inhibit T cell responses by cell contact dependent mechanisms. These mechanisms 
of immuno-immunosuppression are mediated by inhibitory receptor, as CTLA-4 (Cytotoxic T-
Lymphocyte Antigen 4 or CD152) and PD-1 (Programmed Death 1 receptor or CD279). PD1 is an 
immunoinhibitory receptor that belongs to the CD28 family with a is a critical role in the 
regulation of T cell activation and function during immunity and tolerance.  
Fig. 5. Metabolic suppression pathway: a. Regulatory T (TReg) cells produce adenosine following sequential 
degradation of ATP/ADP via CD39 (ENTPD1; ectonucleoside triphosphate diphosphohydrolase 1) and CD73 
(ecto-5'-nucleotidase) b. Adenosine activates A2A receptors on T-effector cells to inhibit T-cell receptor 
(TCR)-mediated signalling by preventing ZAP70 phosphorylation and activation of the transcription factor 
activator protein 1 (AP1). This decreases interleukin 2 (IL2) production and CD25 expression resulting in 
decreased T effector cell proliferation. In addition, it decreses the development of both T helper 1 (TH1) and 
TH2 cells, as well as the generation of TH17 lymphocytes [76]. 
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It is upregulated on T cells upon their activation and highly expressed on Tregs.  
Its ligand, PD-L1, is expressed on antigen presenting cells (APCs) such as dendritic cells, 
macrophages and B cells, T cells, and a variety of nonhematopoietic cells including vascular 
endothelium, and at sites of immune privilege including the placenta and the eye. PD-L2 
expression in contrast was reported to be elevated on DCs from the lung and from draining 
pulmonary lymph nodes after antigen exposure. Interactions between PD-1 and its ligands, help to 
regulate the balance between stimulatory and inhibitory signals needed for regulate the balance 













 This receptor was first observed in T cells undergoing cell death, but several studies, involving 
PD1, have demostrated an important role in tumor immunity (47) and autoimmune disease (48).  
Instead, the contribution of PD1 pathway to the development of allergic airway responses in 
bronchial asthma has recently been recognized (49-50). 
 
2. Allergy 
Allergy is one of the most widespread diseases of the modern world. The term allergy was 
originally defined by Clemens Von Pirquet to describe “an altered capacity of the body to react to 
a foreign substance”. 
Although the immune system protects the organism against disease, the normally protective 
immune mechanisms can sometimes cause injurious reactions in the host, as a consequence of 
deregulated immune responses; these reactions are known as hypersensitivity reactions [1, 2]. 
Fig. 6.  Cell- contact dependent mechanisms: PD-1 on Treg cells down-regulate or prevent the up-
regulation of MHC class II and co-stimulatory molecules on APC upon interaction with their ligand, which 
limits effector T cell activation [64]. 
 16 
 
“Allergy is a hypersensitivity reaction initiated by immunological mechanism”, as defined by the 
EAACI nomenclature task force, and it is one of the most widespread diseases of the modern 
world [51].  
Allergic disorders are associated with the production of allergen-specific IgE and the expansion of 
allergen-specific T-cell populations (Th2 cells). These disorders are due to an aberrant immune 
response, against various harmless environmental proteins (known as allergens), mediated through 
key effector cells, the Th2 cells and an associated cytokine pattern including IL-4, IL-5, and IL-13 
[52]. 
The allergic inflammation is often classified into three temporal phases. Early-phase reactions are 
induced within seconds to minutes of allergen exposure. During this phase, differentiated Th2 cells 
are able to produce large amounts of IL-4 and IL-13, which are essential in the induction of class 
switching recombination of the immunoglobulin heavy chain in B cells and the subsequent 
production of allergen-specific IgE antibodies. Once formed and released into the circulation, IgE 
binds to the high affinity receptor FcεRI, on the surface of mast cells and basophiles as well as to 
Antigen Presenting Cells (APCs), which in turn allows for an increased uptake of allergens. Upon 
re-exposure, allergens activate inflammatory cell recruitment and induce the release of 
inflammatory mediators, which are responsible for Early (EARs) and Late Allergic Responses 
(LARs). The early allergic response occurs within minute of contact with allergens, the binding of 
the allergen to IgE initiates a process of intracellular signaling, which leads to degranulation of 
cells, with the release of inflammatory mediators, such as histamine and leukotrienes, these 
substances cause immediate allergic inflammation and promote vascular permeability, smooth-
muscle contraction and mucus production.  
The second phase, called late-phase reactions (LARs) occurs within several hours after the first 
allergic symptoms and can last for days or even weeks. During the late-phase reaction, mast cells 
responding to allergen release a wide range of newly synthesized cytokines, chemokines and 
growth factors that cause an influx of eosinophiles and Th2 cells. Eosinophiles are the major cell 
type involved in allergic inflammation, and upon activation they release inflammatory mediators 
and cytotoxic proteins (including major basic protein, eosinophil peroxidase and eosinophil-
derived neurotoxin). Finally, when allergen exposure is continuous or repetitive, a chronic allergic 
inflammation develops; this persistent inflammation occurs at sites of repeated allergen exposure 





















The immunological processes leading to the development of the pathogenesis of allergy are 
relatively defined, but it remains to understand why some individuals respond to allergen exposure 
with atopic immune responses and others do not. It is well known that both genetic and 
environmental factors are involved. Interestingly, the increase in atopic disorders observed has 
been partly attributed to an increase in the industrialization and development of countries. 
Moreover, epidemiologists have studied that the increased prevalence of allergic diseases is 
associated with a reduced microbial exposure [55-56]. The hygiene hypothesis, proposed by 
Strachan 1989, asserts that a reduced microbial stimulation of Toll-like receptors (TLRs, a type of 
pattern recognition receptor) on cells of the innate immunity, i.e. dendritic cells (DCs) and natural 
killer (NK) cells in early life is associated with an increasing propensity for allergy sensitization. 
In accordance to this theory the exposure to microbial antigens during childhood prevents the 
development of an allergen-specific Th2 response towards an allergen-specific Th1 response [56]. 
 
Fig 7. Schematic representation of allergy pathophysiology.  In atopic individuals, first exposure to an 
allergen leads to activation of Th2 lymphocytes and stimulation of IgE synthesis. Upon re-exposure, 
binding of the allergen to IgE causes mast cell degranulation and further activation of Th2 cells with 
resulting eosinophil inflammation [54]. 
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2.1. Cytokines and allergy 
Allergic diseases are complex inflammatory disorders that involve many cytokine pathways. Many 
studies show, that allergic disease represents a specialized form of T cell-mediated immunity, 
where T CD4+ cells, particularly Th2 cells, and their products play a central role in the 
development and the persistence of chronic inflammation. It has been thought that the Th2 cell-
cytokines have been involved in triggering hypersensitivity disorders such as allergy. 
In allergic patients, Th2-type cytokines lead to the development of allergic symptoms following 
exposure to allergens. Th2 cells orchestrate the allergic response through the secretion of a series 
of cytokines, such as IL-4, IL-5 and IL-13, which act to enhance the allergic inflammation that 
may lead to chronic inflammation in tissues often exposed to allergens. IL-4 is crucially involved 
in the development of allergic responses. This cytokine induces T naïve cell polarization bias the 
Th2 cells, this cytokine promotes the ε isotype switch and secretion of IgE by B lymphocytes, 
recruits basophiles, eosinophiles and monocytes. Besides, IL-4 enhances IgE-mediated immune 
responses through the upregulation of IgE receptors on the cell surface: both the low-affinity IgE 
receptor (FcεRII or CD23) on B cells and mononuclear phagocytic cells and the high-affinity IgE 
receptor (FcεRI) on mast cells and basophiles [57-58].  
Other cytokines produced by activated allergen-specific Th2 cells that also contribute to the 
pathogenesis of allergic asthma are IL-5 and IL-13. IL-5 has been associated with the cause of 
several allergic diseases, such as nasal rhinitis, asthma, and atopic dermatitis. 
It has been recognized as the major maturation and differentiation factor for eosinophiles during 
allergic inflammation. In fact, it is selective for eosinophiles and basophiles and it is well known 
that these cells are the two main effector cell types involved in allergic inflammation. The 
secretion of this cytokine causes the massive influx of eosinophiles into the lung during the course 
of an allergic response [59]. IL-5 binding to its receptor modulates various functions of 
eosinophiles, including expansion and differentiation of eosinophile precursors, upregulation of 
expression of its own specific α receptor chain during human eosinophile development, cellular 
adhesion, chemotaxis, degranulation, cytotoxicity, prolonged survival and activation. Eosinophiles 
contain numerous basic and cytotoxic granule proteins (including major basic protein, eosinophile 
peroxidase and eosinophile-derived neurotoxin) that are released upon activation [59-60]. These 
proteins could result in being toxic for the respiratory epithelium and may cause 
bronchoconstriction. Since, the eosinophiles are the major cell type involved in allergic 
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inflammation, IL-5 has been proposed as an excellent therapeutic target in allergic diseases. The 
current therapies include two monoclonal anti-IL-5 antibodies (mepolizumab, reslizumab) and a 
monoclonal antibody directed at the IL-5 receptor (benralizumab). Therapeutic strategies aimed at 
the inhibition of IL-5 and or the reduction of serum IL-5 levels may be a promise in the treatment 
of eosinophilic diseases as well as allergies [61]. IL-13 is another Th2-derived cytokine, which 
shows similar effects to those of IL-4. IL-13 induces Igε gene transcription in B cells, which 
subsequently results in class switching towards the IgE isotype as well as IL-4. Unlike IL-4, it is 
not able to regulate T cell differentiation of Th0 into Th2 cells. IL-13 is able to regulate the Th2-
mediated response via its ability to stimulate gene expression of a variety of gene such as those 
coding for adhesion molecules, chemokines, and metalloproteinases in order to promote the 
recruitment, homing, activation and survival of a wide range of inflammatory cells [62-63]. Il-13 
is able to induce a multitude of effects on airway epithelial cells resulting in an increment of 
mucus production by submucosal glands and epithelial cells [64].  
This cytokine induces the production of chemokines that can synergize with IL-5 to selectively 
recruit eosinophiles to the lung. IL-13 is suspected to be the central mediator in the development 
of allergic response and it has been proposed to be mainly involved in the chronicity of allergic 
inflammation, and to play a critical role in the development of asthma [65-66]. Studies in mouse 
model of allergic disease have shown that inhibition of IL-13, by genetic knockout or IL-13 
binding proteins or even the anti IL-13 receptor, could be therapeutically beneficial [66-68].  
 
2.2. Natural Killer (NK) cells and their role in allergy  
The role of T cells and cytokines associated pattern in allergy have been well characterized, but 
little is known about the role of innate immunity cells. It is known that the imbalance of Th1/Th2 
T-cell polarization and the bias towards Th2 cytokine production plays an important role in both 
the initiation and maintenance of these events. It is well known that allergic diseases involve not 
only Th2 cells, but much rather involve more complex immune disorders [39]. Recent studies have 
suggested a role for NK cells in allergy, showing defects in CD56bright CD16dim NK cells in allergic 
patients compared to healthy individuals [69-70]. These observations have suggested that these 
cells might play a role in bias towards Th2 response in poly-allergic patients and healthy 
individuals. NK cells are considered versatile immunomodulatory cells, it has been shown that 
human NK cells are able to polarize in vitro into two functionally different subsets NK1 or NK2, 
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producing cytokine subsets similar to Th1 and Th2 cells. NK cells grown in the presence of IL-12 
(NK1) produce predominantly IFN-γ, whereas NK cells grown in the presence of IL-4 (NK2) 
produce IL-5 and IL-13.  NK cells support DCs to the induction of appropriate T CD4+ responses 
[68-70]. Studies in healthy patients reported that, during a tolerogenic immune response, 
components of the innate immune system (CD56bright CD16dim cells) are activated by allergens to 
produce IFN-γ an IL-10 cytokines. Moreover, in contrast to the diminished levels of IFN-γ+CD56+ 
NK1 cells, high levels of IL-4+CD56+ NK2 cells in PBMC of asthmatic patients have been shown. 
The cytotoxic capacity of NK cells in patients with allergic rhinitis was also higher compared with 
that seen in healthy subjects. There are good evidences that NK cells also take part in allergic 
diseases through their contribution to allergen-specific immune suppression and IgE production 
[71-75].  
 
2.3. T regulatory cells and their role in allergy 
The initial immune model of the Th1/Th2 imbalance associated with the ‘hygiene hypothesis’ has 
recently been questioned by further evidences that peripheral T-cell regulation plays a crucial role 
in the control of harmful T-cell responses [76].  
It has been proposed that an impairment in the induction of regulatory responses is the underlying 
mechanism involved in the differentiation of pathogenic T cells driving to inflammatory responses 
including aberrant Th2 response that drives to allergic diseases. Our immune system consists of a 
complex network of regulatory response that maintain the immune homeostasis.  
Moreover, the description of a new subset of CD4+ T cells named Tregs revisited the “immune 
regulation” concept.   
Tregs are the main cells involved in the regulation of both innate and adaptive immune response. 
This feature makes these cells important in maintaining peripheral immune tolerance and more 
generally in the control of immune response against tumors, viral infections and transplants. 
Defects in their function can induce inflammation and autoimmune diseases [77-79].  
In recent years Tregs have been described as key mediators during the sensitization phase of 
allergic response. Studies on immune response to allergens in healthy non-atopic individuals 
showed that Tregs play a crucial role in preventing Th2 response to allergens and maintaining the 
peripheral tolerance. On the contrary, the T regulatory function results impaired in allergic 
individuals. Therefore, the activation of Th2 response to allergens is a consequence of an impaired 
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mechanism of tolerance that is normally characterized by T cell anergy and Treg activity mediated 
by secretion of suppressive cytokines such as IL-10 and TGF-β [80-81]. Studies on allergic murine 
models showed that the depletion of Tregs during the sensitization phase led to the development of 
allergic inflammation, with increased recruitments of inflammatory cells, secretion of Th2 
cytokines and high levels of serum IgE pointing out the pivotal role of Treg cells in the regulation 
of immune response to allergens. However, the allergic inflammation can be suppressed and the 
immune response restored by the adoptive transfer of Treg expressing IL-10 and TGF-β. 
Therefore, the possibility to control Treg function could have many therapeutic potentials for the 
treatment of allergy. Many studies have been carried out to characterize Treg phenotypes and 
biological activity.   
 
3. Allergen-Specific ImmunoTherapy (SIT) 
During the last decades, the prevalence of allergic diseases has increased dramatically in the 
industrialized high-income countries. 
The World Health Organization (WHO) reports Non-Communicable Diseases (NCDs) to be the 
major cause of adult mortality and morbidity in the world. Chronic respiratory diseases are the  
third main cause of death after cardiovascular disease and cancer. The allergic diseases are the 
most common chronic respiratory diseases worldwide. 
The prevalence of allergic diseases has dramatically increased over the past decades, affecting up 
to 30% of the population in industrialized countries. The understanding of the mechanisms 
underlying allergic diseases, as well as those operating in non-allergic healthy responses, plays an 
important role in the development of new therapeutic strategies for allergic disease.  
Several potential therapies have been proposed for the treatment of allergic diseases. It is possible 
to impair the activation of allergen-specific Th2 cells, either directly or indirectly, inhibiting 
antigen-presenting cells: for example by treatment with anti-inflammatory drugs, such as 
glucocorticoids.  
Another therapeutic option for the treatment of allergic diseases is to inhibit effector molecules 
that cause the allergy clinical symptoms: such as the treatment with antihistamines, leukotriene 
antagonists as well as neutralizing antibodies specific for Th2 cytokines or antibodies specific for 
IgE. Therefore, various drugs can transiently ameliorate the symptoms of IgE-mediated allergy 
reactions, but although these treatments are highly effective for controlling allergic diseases they 
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are not able to modify the natural history of the allergic diseases [82-84].  
The only valid treatment able to modify the underlying pathological mechanisms of immune 
response and to have a long-lasting effect is allergen-Specific ImmunoTherapy (SIT) which was 
first introduced by Leonard Noon in 1911 [85]. 
He originally hypothesized that patients suffering from hay fever were sensitive to a “toxin" 
contained in grass pollen that caused allergic symptoms [85-87]. He suggested that the inoculation 
of small doses of pollen extracts would induce antitoxins and be of benefit for the patient.  
This procedure consists in giving increasing amounts of allergen extracts into the patient with the 
aim to reduce the symptoms on a re-exposure to those particular allergens.  
This principle is still true today, more than 100 years later, and it is the basis for current allergen 
immunotherapy. The repeated administration of allergens to allergic individuals has the aim of 
modifying the allergen-specific immune response and of activating immunomodulatory 
mechanisms in treated patients, in order to induce tolerance towards higher doses of allergen and 





















Fig. 8. Mechanism of immunological tolerance induced by repeated administration of high doses of 
allergens. Low-dose and repeated allergen exposure at mucosal surfaces in atopic individuals drives IgE-
facilitated antigen presentation and Th2 mediated allergic inflammation. High-dose allergen administered by 





Several studies have demonstrated the efficacy of allergen-specific immunotherapy, but although it 
is a clinical practice used for almost one century, the molecular mechanisms involved in successful 
immunotherapy are not fully understood and several factors seem to influence the immune 
response such as the concentration of the allergen, the type of antigen-presenting cells and the type 
of adjuvants used for the formulation of vaccine. 
So far, allergen-specific immunotherapies have been carried out with allergen extracts from 
natural sources that have often shown great variations of allergen contents without taking care of 
the individual sensitization profile of patients. Several studies have reported that the administration 
of natural allergen extracts could induce new IgE specificities against allergens, which were in the 
natural extracts and not recognized by the patient before treatment. The main disadvantages that 
limits the use of allergen extracts from natural source in SIT are related to their heterogeneity and 
poor quality of these extracts which may lack important allergens and also show non standardized 
composition [88-91]. 
Many strategies have been developed in order to reduce systemic anaphylactic reactions during 
SIT and overcome the IgE-mediated side effects observed with allergen extracts. 
The use of recombinant purified allergens can overcome many, if not all, of the problems 
associated with the use of natural allergen extracts, such as poor quality, allergenic activity and 
poor immunogenicity [85, 92-94]. Thanks to recombinant DNA technology, cDNAs of most 
important allergens have been isolated and expressed as recombinant proteins. The number of 
cloned and purified allergens has increased substantially over the past decade. This allows the 
production of pure allergen molecules in order to produce defined and safe allergy vaccines.   
The use of recombinant ‘native’ allergens, which retain the sequence, conformation and biological 
activity of the natural molecule, has several advantages over the use of natural allergen extracts. 
Recombinant ‘native’ allergens are effectively proteins that can be produced under defined 
conditions and purified by using procedures such as affinity chromatography [88]. Some reports 
about allergen-specific immunotherapy performed with recombinant allergens have been 
published, showing the efficacy of these vaccines for the treatment of allergic disorders [93-94]. 
During an allergen immunotherapy trial, in 2006, birch pollen allergic patients received 
recombinant Bet v 1a allergen; the results of this study showed that the treatment with 
recombinant allergen Bet v 1a was as effective as the treatment with the natural extract [95-96]. 
Moreover, several studies have shown that immunotherapy with high doses of allergens was more 
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effective than that with low doses for symptom reduction. However, the administration of 
increasing doses of recombinant ‘native’ allergens to patients may induce severe and life-
threatening IgE-mediated anaphylactic side effects. Therefore, effective dosages are limited by 
potential systemic reactions [97]. 
To overcome this problem, the development of recombinant DNA technology has allowed to 
modify the major allergens in vitro and to create hypoallergenic variants with reduced allergenicity 














Different approaches can be used to produce hypoallergenic variants with reduced IgE binding 
activity but they have to preserve the sequence and structural motifs necessary for T-cell 
recognition, termed T-cell epitopes, and for induction of IgG antibodies reactive with the natural 
allergen (blocking antibodies) [98]. 
Studying the relationship between the structure of the allergen and its function is a pre-requisite 
for the manipulation of a gene. The allergen gene modification usually requires knowledge of B 
and T cell epitopes. The reduction of IgE binding activity can be obtained either by mutation 
and/or deletion of crucial amino acid residues involved in IgE recognition or by the disruption of 
the three-dimensional structure of the allergens. This, can also be obtained by fragmentation, or by 
oligomerization, or by fusion of allergen variants [99-101]. 
A novel approach to negatively regulate immune response to allergen is the generation of 
recombinant hybrid allergen proteins. Hybrid allergenic molecules are proteins consisting 
Fig. 9. Approaches for the generation of hypoallergenic allergy vaccines [86]. 
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of multiple allergens (either omo- or etero-) fused in an engineered single molecule. Hybrid 
allergenic molecules can contain two or more recombinant native allergens or alternatively contain 
the most important epitopes or polypeptides of one or more allergens.  Some of these molecules 
can also retain T-cell epitopes and lack the IgE reactivity of the native molecules. These hybrid 
allergen proteins have been created for the use as combination vaccines; an applicable strategy 
whenever the induction of simultaneous immune responses against unrelated antigens with 
different immunogenicity is desired. The advantages of this strategy have been shown by a few 
reports where oligomerization induced immunological changes like reduced allergenicity and 
increased immunogenicity [102]. 
 
3.1. Immuno deviation during SIT  
A healthy immune system is dynamic and balanced between Th1 and Th2 cell responses and it is 
able to change between the two cell-mediate responses as needed. Th1 and Th2 regulate immune 
system function in a delicately balanced relationship. However, both genetic and environmental 
factors could cause a Th1 or Th2 dominant-response and induce an immune disorder. Thus, when 
Th1 cells are overactive they can suppress the Th2 mediated immune response and vice versa. 
Allergen specific Immunotherapy has been shown to modify T cell response in several ways. [103-
104]. T cells are considered to be the main immune cells involved in the modification of allergic 
immune response during allergen specific immunotherapy. The shift from Th2 cells, that 
characterize the atopic immune response, to the protective Th1 response, is induced by the 
administration of repeated high doses of allergen, as occurs by specific immunotherapy. Allergen-
specific immunotherapy alters the balance of cytokines produced by T helper lymphocytes, by 
modulating or down regulating the production of cytokines such as IL-4, IL-5 and IL-13, and by 
inducing the upregulation of IFN-γ associated with the induction of an ameliorating Th1 response.  
Clinical evidence suggests allergen immunotherapy induces a Th1-redirection of immune response 
by modifying peripheral and mucosal predominant Th2 response into a protective Th1-
polarization, as evidenced by a reduced Th2 cytokine level and an increased production of IFN-γ 
and IL-10 cytokines [105]. 
IFN-γ is a pleotropic cytokine that plays an essential role in both the innate and adaptive phases of 
an immune response. An important role of IFN-γ is to activate antigen-presenting cells (APC), 
such as dendritic cells and macrophages, resulting in increased phagocytosis, increased MHC class 
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I and II expression.  It induces the production of IL-12 and reactive oxygen species, which are 
important in the elimination of intracellular pathogens. IFN-γ acts not only as a potent activator of 
the Th1 phenotype, but also as a suppressor of Th2 development, exercising inhibitory effects on 
Th2 cytokine production [106]. 
In line with this evidence, IFN-γ and IL-12 may suppress Th2 responses of allergic diseases. 
Epidemiological studies have clearly shown that a failed Th1 response, characterized by the cell-
mediated pro-inflammatory response through the production of IFN-γ, predisposes towards the 
development of allergic diseases. Moreover, patients with severe asthma present a reduced level of 
IFN-γ in response to allergen if compared to healthy patients [106].  Another inhibitory role of 
IFN-γ is its ability to regulate the switching of heavy chain class into antibody-secreting B cells, 
inhibiting immunoglobulin class switching to IgE. Otherwise, IFN-γ induces IgG4 production, 
which acts as a competitive response to that of specific IgE, by blocking IgE-facilitated antigen 
presentation. IgG4 are also able to neutralize inhaled allergens, through the interactions with Fcγ 
receptors (FcγR), promoting FcγR-mediated endocytosis of allergen-IgG complexes [106]. Th1 
and Th2 are implicated in inflammatory reactions, so as to minimize the damages of these 
reactions; the allergen immunotherapy triggers an anti-inflammatory immune response.  
IL-10 plays a key regulatory role in peripheral tolerance during allergen specific immunotherapy 
and natural exposure to allergen. This cytokine acts as a general inhibitor of proliferative and 
cytokine response of both Th1 and Th2 [107]. 
IL-10 is produced by a large number of immune cells (B lymphocytes, macrophages and DCs) in 
addition to the regulatory CD4+ T cells. The repeated administration of allergen induces a state of 
peripheral anergy in specific T cells, which is characterized by blocked CD28 co-stimulatory 
signaling and suppressed proliferative and T-cell cytokine responses. 
IL-10 is a potent anti-inflammatory and immunosuppressive cytokine that mediates its major 
immunosuppressive function by inhibiting APC functions and cytokine production of 
macrophages and dendritic cells and inhibiting Th1 cell-mediated immunity [107-108]. IL-10 can 
also suppress the allergic response reducing pro-inflammatory cytokine production by Th2 cells 
and inducing Th2 cell anergy by acting directly on these cells and through other immune cells 
[108]. 
The IL-10 produced by allergen specific Tregs suppresses allergic inflammation also through 
direct action on mast cells, basophiles and eosinophiles. Another critical role of IL-10 is its ability 
to promote the survival, proliferation, and differentiation of human B cells. It has two different 
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effects on B cells; it can differently modulate Ig responses by inhibiting IgE production and 
enhancing the production of blocking IgG4.  
The knowledge of these molecular mechanisms is fundamental in understanding the regulation of 
immune response and the immunological process involved in peripheral tolerance and their 
possible therapeutic applications. 
 
4. Parietaria judaica (Pj) 
Parietaria judaica is a species of herbaceous perennial plant belongs to genus of dicotyledonous 
weeds of Urticaceae family. This family is considered to be the most common group of allergenic 
plants in the Mediterranean area and P. judaica and P. officinalis have been reported to be the 
most common causes of allergy in this area. The Parietaria pollen shows very strong allergenic 
properties that give rise to seasonal allergies with clinical manifestations such as rhinitis, 
conjunctivitis and asthma. Parietaria judaica has a very long period of pollination, from February 
to September. In the southern regions and islands, this period is often biphasic with a first phase 
that starts around the months of February-March and then reaches its peak in the months of April-
May; while in the northern regions there is only one peak in the period of May-June. Parietaria 
pollen is one of the main sources of allergens in Mediterranean area. In fact, about 30% of all the 
allergic subjects in southern Italy present a skin prick test (SPT) reactivity to the Parietaria 
judaica (Pj) pollen extract [109]. 
 
4.1 Parietaria judaica allergens 
Recombinant DNA technology allowed to isolate and characterize the Parietaria judaica 
allergens.  The composition of the allergenic extract of Parietaria judaica pollen has been studied 
and its allergens have been identified and characterized by immunochemical and molecular-
biological techniques [109]. Among them, Par j 1 and Par j 2 were classified as the two major 
allergens of Parietaria pollen, which belong to the family of the non-specific Lipid Transfer 
Proteins (ns-LTPs) [110-112]. These proteins are widely distributed in the plant kingdom and form 
multigene families of related proteins, characterized by their ability to transport lipid molecules 
through membranes in vitro. Recent studies have shown that the ns-LTPs have a protective 
function, such as antimicrobial activities and are thought to participate in plant defense 
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mechanisms. This hypothetical function is also supported by the induction of the expression of 
many ns-LTP genes in response to biotic infections or application of fungal elicitors and by the 
enhanced tolerance to bacterial pathogens. Due to their possible involvement in plant defense 
mechanisms, nsLTPs are recognized to be pathogenesis-related (PR) proteins and constitute the 
PR-14 family. Two minor allergens have recently been isolated from Parietaria pollen: the Par j 3, 
showing high similarity to profilins and the Par j 4 with high level of similarity to calcium-binding 
proteins from other allergenic sources [113-114]. 
Besides, two different isoforms of Par j 1 have been isolated and named Par j 1.0101 (a 14,4 kDa 
protein) and Par j 1.0201 (a 10,7 kDa protein). These proteins are isoallergenic forms of the major 
allergen Par j 1. These isoforms demonstrated a 96% amino acid sequence similarity within the 
first 102 amino terminal regions. Overall, the two isoforms differ for the presence of a 37 
aminoacids COOH-terminal tail in the Par j 1.0101 allergen [115-116]. 
Bonura et al studied the correlation between the pairing of disulfide bonds and the human IgE-
binding activity. In particular, Par j 1 and Par j 2 have a characteristic structure stabilized by four 
disulfide bonds. Hypoallergenic molecules were generated by targeting these disulfide bonds 
through site-directed mutagenesis of specific cysteine residues with serine. These molecules 
showed an altered conformation and a decreased IgE-binding activity but a maintained T cell 
reactivity.  
In a published paper the authors described the immunological characterization of hypoallergenic 
mutants of Par j 1 developed by site-directed mutagenesis [117].  
Four different variants of the major allergen of Par j 1 were constructed by changing the three-
dimensional structure carrying serine substitutions of cysteine residues into positions 4, 29, 30, 50 
and 52 [117]. The same approach was used for the Par j 2 allergen.  
Recently, the Par j 1 hypoallergens were evaluated in vivo in a murine model of allergic 
sensitization. Another published paper by Bonura et. al. described a hybrid hypoallergenic 
molecule, named rPjEDcys, generated by head to tail fusion of the two major Parietaria allergens, 
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Fig. 10 Schematic representation of rPar j 1, rPar j 2 and engineered rPjEDcys. 
 
The advantages of this strategy have been shown by few reports; oligomerization induces 
immunological changes like reduced allergenicity and increased immunogenicity. In accordance 
with these data, rPjEDcys displayed a reduced allergenicity and retained T cell reactivity. 
The reduced allergenic activity of rPjEDcys combained with it retained immunogenicity was 
demonstrate by human in vitro studies that showed rPjEDcys retained the capability to stimulate 
CD3+ cell proliferation and in mouse in vivo studies in which BALB/c mice immunized with the 
rPjEDcys induced antibodies studied for their ability to bind allergens of Parieteria pollen.  
Moreover, the immunogenicity of the hypoallergenic hybrid was studied in vivo looking at the 
pattern of antibody production in a mouse model of sensitization. BALB/c mice were immunized 
with the hybrid and the induced antibodies were studied for their ability to bind the major allergens 
of the Parietaria pollen. Despite of the changes introduced by mutagenesis, the rPjEDcys was able 
to induce a strong IgG response towards the rParj1 and rParj2 molecules. Both ELISA inhibition 
and western blot experiments performed with the Parietaria pollen extract demonstrated that the 
rPjEDcys induced IgG antibodies were able to recognize the natural major allergens. This 
suggested that an immunization protocol performed with the recombinant hybrid could induce Par 
j 1 and Par j 2 specific antibody responses. These responses could be capable of inhibiting IgE 
mediated presentation, blocking basophile histamine release and reducing seasonal IgE production 






The aim of this research project is to study the immunological mechanisms activated by the major 
allergens of Parietaria judaica, rPar j 1 and rPar j 2, and the hybrid hypoallergenic mutant  
rPjEDcys containing their main B and T-cell epitopes in one molecule. Despite their common 
evolutionary origin in fact, Par j 1 and Par j 2 allergens display some cross-reactive and 
independent IgE epitopes. The project I am involved in is to address the question whether this 
engineered hypoallergenic molecule can be used as a potential pharmaceutical product for a safer 
allergen-specific immunotherapy. 
Therefore, the generation of a single protein comprising the two major allergens of Parietaria 
pollen as pharmaceutical product may reduce production costs, providing a therapy that could 
modify allergen-specific immune response towards the two major Parietaria allergens. 
The use of rPjEDcys in the treatment of allergy may present many advantages with respect to the 
natural extracts used:  
1) one pharmaceutical product to protect against Par j 1 and Par j 2 sensitivity; 
2) a characterized and standardized product;  
3) a safer product with reduced anaphylactic activity. 
 
However, there is a need of a new insight into the mechanisms of inflammatory and allergic 
diseases. 
The study of the processes at molecular level enables us to better understand the regulation of the 
immune responses. Intensive studies have to be performed to understand the mechanisms of action 
of allergen specific immunotherapy in order to decrease the side effects and increase the efficiency 
of the current therapies and to develop novel therapies. 
Therefore, in this experimental setting, the use of the major allergens of Parietaria judaica and the 
hybrid allowed me to study the immunological mechanisms activated by the major allergens of 
Parietaria judaica, Par j 1 and Par j 2, and to investigate the differences between the wild type 
allergens and the hypoallergenic mutant rPjEDcys. 
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Material and Methods 
 
1. Production of recombinant proteins 
The recombinant allergens (Par j 1, Par j 2 and PjEDcys) were expressed as histidine-tagged 
proteins (pQE30 vector, Qiagen, UK) in Escherichia coli (strain M15, Qiagen, UK). Recombinant 
clones were grown over night at 37°C in 10 ml of 2YT broth (Bacto-tryptone 16g/l, yeast extract 
10 g/l and NaCl 5g/l at pH 7.0) containing 100 µg/ml ampicillin. The bacteria were diluted 1:40, 
incubated for 2 hours at 37°C. Isopropylthio-β-galactoside (IPTG) was added to the final 
concentration of 1 mM and growth was continued for a further 3 hrs. Cells were harvested by 
centrifugation (5,000 rpm for 15 minutes at 4°C) and disrupted by using a sonicator device (Heat 
System Ultrasonic W-285) in a starting buffer containing 10 mM of sodium phosphate, 0.5 M 
NaCl (for rPar j 2 and rPjEDcys) or 1 M NaCl (for rPar j 1), 10 mM imidazole and and 6 M urea at 
pH 7.4 The cell lysates were centrifuged at 10,000 rpm for 10 minutes to remove cell debris. 
Following the lysis, the lysate becomes very viscous due to the release of genomic DNA into the 
solution. It is very important to reduce viscosity and to avoid clogging of the column. Therefore, 
supernatant was filtered through a sterile 0.8µm syringe disc-type filter to disrupt genomic DNA 
and used for purification of the proteins. 
1.1. Affinity chromatography  
Proteins were purified by using HisTrap chelating Column (GE Healthcare, Hertfordshire, UK) 
equilibrated in starting buffer. The column was washed in wash buffer (10 mM sodium phosphate, 
0.5 or 1 M sodium chloride, 50 mM imidazole and 6 M urea at pH 7.4) to reduce unspecific 
binding and to remove the contaminants. Histidine-tagged proteins were eluted by using a 
discontinuous imidazole gradient (elution buffer: 50–500 mM imidazole). The eluted proteins 
were diluted 1:50 in starting buffer without imidazole and reloaded onto a HisTrap chelating 
column for a second purification phase. Eluted fractions were analyzed by SDS-polyacrylamide 
gel and stained with Coomassie Brilliant Blue. 
1.2. Dialysis  
Refolding of the solubilized proteins is initiated by the removal of the urea by means of dialysis, 
using membranes with molecular cutoff of 3.500 Da. The fractions containing the recombinant 
allergens were first pooled and diluted 1:20 in starting buffer and dialysed against a buffer 
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containing 10 mM sodium phosphate and 0.5 or 1 M sodium chloride, at pH 7.4 for 90 minutes.  
1.3. Second affinity chromatography  
After dialysis, a third purification step is performed using buffers that do not contain urea. The 
sample was recovered and reloaded onto another HisTrap chelating Column (GE Healthcare, 
Hertfordshire, UK) equilibrated in starting buffer without urea. The column was washed in a wash 
buffer and the histidine-tagged proteins have been eluted by using a discontinuous imidazole 
gradient (50–500 mM). Eluted fractions were analyzed by SDS-polyacrylamide gel and stained 
with Coomassie Brilliant Blue.  
1.4. Gel filtration chromatography  
Eluted fractions containing recombinant proteins were desalted using a Sephadex G-25 Superfine 
column (GE Healthcare, Hertfordshire, UK). Sephadex G-25 is a well-established gel filtration 
medium for desalting, separations of low and high molecular weight molecules and buffer 
exchange. The positive fraction was loaded onto Sephadex G-25 superfine column equilibrated in 
1X Phosphate Buffered Saline (PBS) solution without Ca2+ and Mg2+ (Dulbecco's phosphate-
buffered saline (D-PBS)) and the recombinant proteins were then eluted usin 1X PBS solution. 
Eluted fractions were analyzed by SDS-polyacrylamide gel and stained with Coomassie Brilliant 
Blue. 
1.5. Detoxi-Gel Endotoxin Removing Gel 
Many recombinant proteins are expressed in Escherichia coli vectors. These products are always 
contaminated with endotoxin derived from the outer cell membrane of gram-negative bacteria. 
Due to the diverse and potentially harmful biological response to these molecules, the presence of 
endotoxins in biologically derived products prepared for therapeutic use is a major problem.  
Detoxi-Gel Endotoxin Removing Gel (Pierce, USA) is commonly used to remove endotoxins from 
protein solution. This technique uses immobilized polymixin B, a peptide antibiotic that has a very 
high binding affinity for the lipid A of most endotoxins, allowing its removal from solution. 
Detoxi-Gel Endotoxin Removing Gel was regenerated in 5 ml of 1% sodium deoxycholate in 
sterilized water and washed with 5 ml of sterilized water and 5 ml of PBS 1X before the fraction 
containing recombinant protein was added. The recombinant proteins (rPar j 1, rPar j 2 and 




1.6. Protein quantification assay 
Protein concentration was determined by reference to a standard curve with known concentrations 
of Bovine Serum Albumin (BSA). Protein calibration curve was constructed using BSA at 
concentrations of 250 ng/µl, 500 ng/µl, 750 ng/µl and 1000 ng/µl. A calibration curve of fraction 
that has an unknown protein concentration was prepared with an increasing quantity of protein 
solution. The samples were analyzed by SDS-polyacrylamide gel and stained with Coomassie 
Brilliant Blue and quantification of protein loaded was performed with a Bio-Rad ChemiDoc using 
the software Quantity One. The recombinant proteins were stored at −80°C. 
1.7. Limulus Amebocyte Lysate test (LAL test) 
Each protein was tested for endotoxin content using the Multi-test Limulus Amebocyte Lysate 
(LAL) pyrogen plus test (Bio-Whittaker, VWR International, Milan, Italy) 
This is highest sensitive system of detection and quantification of the amount of bacterial 
endotoxin in a sample, which is derived from the circulating amebocyte of horseshoe crab Limulus 
Polyphemus. The maximum sensitivity is 0.03 EU/ml (λ) (EU = endotoxin units). LAL assay is a 
gel-clot assay, based on the interaction of endotoxins with the proenzyme Factor C found in 
circulating amebocytes. When the LAL is combined with a dilution of the sample containing 
endotoxin, clots upon exposure to endotoxin. LPS contamination is usually expressed in EU / 
micrograms. In order to assess the amount of endogenous LPS, serial dilutions of recombinant 
proteins were made. The first solution was prepared at a concentration of 1 µg of protein in 100 µl 
of water for bacterial endotoxin (LAL reagent water) (Lonza, endotoxin content: <0.005 EU/ml) 
test and serial dilutions of this solution were prepared  (1:1, 1:2, 1:4, 1:8, 1:16) in LAL reagent 
water. The serial dilutions allow us to detect the endpoint dilution, as the last dilution of endotoxin 
that still gives a positive result. The test is not valid without a positive and a negative control. 
Positive control is prepared with 100 µl of standard endotoxin at a concentration of 2λ (0.06 
EU/ml). Negative control contains only 100 µl of LAL reagent water. 
In each vial, a volume of 100 µl of LAL reagent was added to an equal volume of the samples and 
controls. Each dilution, as well as positive and negative controls, was assayed in duplicate. 
The vials were incubated in the heat-stable apparatus at 37 ± 1°C for 60 ± 2 min, avoiding 
vibration. After the one hour incubation period, the positive and negative results were recorded. A 
result was recorded as positive when a gel was formed in reaction tube and remained when the vial 
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was inverted through 180 degrees.  A negative result was indicated by the absence of a gel or by 
the formation of a viscous gel that did not maintain its integrity when inverted. 
LAL test sensitivity allows us to detect an endogenous endotoxin content lower 0.003 ng LPS/µg 
of recombinant protein. 
 
2. Patient selection  
Patients included in the study were over 18. They were chosen, during the Parietaria judaica 
pollen season, for their allergic clinical history towards the Parietaria judaica pollen and for the 
positive skin prick test in response to commercial extracts. 
None of them had previously received treatment with glucocorticosteroid or antihistamine within 
the last months. Patients with uncontrolled asthma or receiving previous Parietaria judaica 
specific immunotherapy were excluded from the study. Each patient signed an informed consent 
before the blood collection. 
 
3. Human Peripheral Blood Mononuclear Cells (PBMC) isolation 
Human Peripheral Blood Mononuclear Cells (PBMC) were isolated from heparinized peripheral 
blood of Parietaria allergic patients, by Ficoll density gradient centrifugation (LYNPHOPREP 
Axis-Shield-Norway). 15 ml of heparinized peripheral blood was diluted (1:1) in HBSS (Hank’s 
balanced salt solution -EUROCLONE-) supplemented with 1X penicillin/streptomycin. The 
sample is centrifuged at 2,500 rpm for 20 minutes at 20°C in a swinging-bucket rotor without 
brake. After centrifugation, the following layers will be visible in the tube, from top to bottom: 
plasma and other constituents, a layer of mononuclear cells (PBMC), Ficoll-Paque, and 
erythrocytes & granulocytes which should be present in a pellet form at the bottom. This 
separation allows an easy harvest of PBMC. The mononuclear cell layer was aspirated and the 
recovered interface was carefully transferred into a new 15 ml conical tube. The recovered cells 
were washed three times in HBSS and then the cells were counted using a Thoma counting 
chamber. The cells were resuspended in complete RPMI (RPMI 1640 with a final concentration 
of: HEPES 25 mM, glutamine 2 mM, sodium pyruvate 2.5 mM, 1X penicillin/streptomycin, 10% 




4. Flow cytometry  
Immunostaining and flow cytometry analyses were performed according to standard procedures.  
All antibodies were purchased from Miltenyi Biotec or BD Biosciences ( Tabel 1). Isotype 
controls for each antibodies were included in all experiments.  
Each samples was incubated for 20 minutes in the dark in the refrigerator (4°C). A minimum of 
100,000 cells per sample were then analyzed a BD FACS Calibur (BD Biosciences, San Jose, CA, 
USA) and CyAn ADP flow cytometer (DAKO) only for multiparametric analyses. Data 
interpretation was performed with WinMDI 2.9 software (Windows Multiple Document Interface 
for Flow Cytometry 2.9), Summit 4.3 software or Flowjo v10.1 software (Tree Star, Ashland, OR). 
Analysis gates were set on live lymphocytes by forward and side scatter profile. 
 
Antibody Fluorocrome Provider Antibody dilution 
anti-CD4  PE (Phycoerythrin) Miltenyi Biotec 1 µl/ 1 X 106 cells 
anti-CD4 PerCP (Peridinin chlorphyll protein) Miltenyi Biotec 1 µl/ 1 X 106 cells 
anti-CD4  FITC (Fluorescein isothiocyanate) Miltenyi Biotec 1 µl/ 1 X 106 cells 
anti- CD8 PerCP (Peridinin chlorphyll protein) Miltenyi Biotec 1 µl/ 1 X 106 cells 
anti-CD14 PerCP (Peridinin chlorphyll protein) Miltenyi Biotec 1 µl/ 1 X 106 cells 
anti-CD16 PE (Phycoerythrin) Miltenyi Biotec 1 µl/ 1 X 106 cells 
anti-CD25  PE (Phycoerythrin) Miltenyi Biotec 1 µl/ 1 X 106 cells 
anti-CD25  FITC-VioBright (Fluorescein 
isothiocyanate) 
Miltenyi Biotec 1 µl/ 1 X 106 cells 
anti-CD39 FITC-VioBright(Fluorescein isothiocyanate) Miltenyi Biotec 1 µl/ 1 X 106 cells 
anti-CD39 PE (Phycoerythrin) Miltenyi Biotec 1 µl/ 1 X 106 cells 
anti-CD56  PerCP-Cy5.5 (Peridinin chlorphyll protein-
Cy5.5 conjugates) 
BD-Bioscience 1 µl/ 1 X 106 cells 
anti-CD127  FITC (Fluorescein isothiocyanate) Miltenyi Biotec 1 µl/ 1 X 106 cells 
anti-GARP  PE (Phycoerythrin) Miltenyi Biotec 1 µl/ 1 X 106 cells 
anti-GARP APC (Allophycocyanin) Miltenyi Biotec 1 µl/ 1 X 106 cells 
anti-LAP  PE (Phycoerythrin) Miltenyi Biotec 1 µl/ 1 X 106 cells 
anti-PD1 PE (Phycoerythrin) Miltenyi Biotec 1 µl/ 1 X 106 cells 
REA Control (S) PE (Phycoerythrin) Miltenyi Biotec 1 µl/ 1 X 106 cells 
Mouse anti-IgG2a PE (Phycoerythrin) Miltenyi Biotec 1 µl/ 1 X 106 cells 





5. 5(6)-Carboxyfluorescein Diacetate Succinimidyl Ester (CFDA-SE) staining 
PBMC from ten allergic patients were resuspended in 1X PBS w/o calcium and magnesium 
(GIBCO) at a concentration of 1 X 107 cells/ml and labeled with a solution containing 5 µM 5(6)-
Carboxyfluorescein Diacetate Succinimidyl Ester (CFDA-SE, Molecular Probes, Nebr.,USA) and 
maintained for 4 minutes at room temperature in the dark. After this period, the reaction was 
stopped by adding ice-cold RPMI medium supplemented with 10% FCS.  
The cells were washed twice in RPMI medium and were resuspended in RPMI complete medium 
with 10% FCS at final concentration of 1 X 106 cells/ml. 
CFSE-labeled cells were incubated with antigen, prepared as described before, at 1 and 10 µg/ml 
for 7 days. Control samples were cells incubated with medium only and cells incubated with LPS 
at 1 µg/ml (Escherichia coli 026:B6, SIGMA). 
After 7 days the cells were collected by centrifugation washed and stained with anti-CD4 PE, anti-
CD8 PerCP, anti-CD16 PE and anti-CD56 PerCP-Cy5.5.  
 
6. Cytokine Secretion Assay: IL-5, IL-13, IFN- γ and IL-10 
Cytokine secretion assay was carried out in order to detect T cell secreted cytokines upon antigen 
specific stimulation. This technique allows the multiparameteric analysis of viable cytokine-
secreting cells down to frequencies of 10-5. It was performed in order to detect and isolate viable 
antigen-specific T cells after a specific in vitro stimulation. T cells secrete cytokines, only 
transiently, upon stimulation and therefore there are normally only very few T cells secreting 
cytokines in peripheral blood. However, memory/effector T CD4+ cells rapidly restart to secrete 
cytokines after an in vitro stimulation.  
In particular, PBMC from ten allergic patients were resuspended in RPMI complete medium with 
10% human AB serum and seeded at a final concentration of 5 X 106 cells/ ml. 
PBMC were incubated with antigen, prepared as described before, at 20 µg/ml for 16 hrs at 37°C, 
5% CO2 and moreover, purified costimulatory anti-CD28/49d were added at a final concentration 
Mouse anti-IgG2a FITC-VioBright (Fluorescein 
isothiocyanate) 
Miltenyi Biotec 1 µl/ 1 X 106 cells 
Mouse anti-IgG1 PE (Phycoerythrin) Miltenyi Biotec 1 µl/ 1 X 106 cells 




of 1 µg/ml each sample. The control sample was treated as the antigen-stimulated sample except 
for antigen addition. 
After 16 hrs, the cells were collected and resuspended in 4 ml of cold buffer (RPMI complete 
medium with 1% human AB serum) at a final concentration of 106 cells/ml and divided into four 
different tubes per sample, in order to investigate four different cytokines, as IL-5, IL-13, IFN-γ 
and IL-10. A total of 106 cells were used for each cytokine secretion assay. 
The cytokine secretion assay involved the following steps:  
1) PBMC were washed by adding 1 ml of cold buffer and centrifuged at 1500 rpm for 5 minutes at 
4°C; after centrifugation supernatant was pipette off completely. 
2) PBMC were resuspended in 90 µl of cold buffer per 106 total cells, adding 10 µl of a cytokine-
specific catch reagent (cytokine-specific ‘catch’ antibody, conjugated with a CD45-specific 
monoclonal antibody that labels all leucocytes equally) and incubated for 5 minutes on ice. 
Afterwards, the cells were resuspended in 14 ml of warm medium (RPMI complete medium with 
5% human AB serum) for 45 minutes at 37°C to allow cytokine secretion. The secreted cytokine 
binds to the cytokine-specific Catch Reagent on the secreting cells; during this step each tube was 
rotated every 5 minutes to resuspend settled cells. The cytokine secretion was stopped by placing 
each tube on ice. Cells were washed with a cold buffer and centrifuged at 1,500 rpm for 10 
minutes at 4°C. After centrifugation, cell pellet was resuspended in 90 µl of cold buffer and the 
cytokines were subsequently labeled with 10 µl of a cytokine-specific "Detection" antibody, which 
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Fig 11. Schematic representation of Cytokine Secretion Assay: after a short antigen specific restimulation 
(a) a cytokine specific Catch Reagent is attached to the cell surface of all cells (b). The cells are then 
incubated for 45 minutes at 37°C to allow cytokine secretion (c). The secreted cytokine binds to the cytokine-
specific Catch Reagent on the secreting cells and is subsequently labeled with a second cytokine-specific 
"Detection" antibody, which is usually conjugated to a fluorochrome like phycoerythrin (PE) for sensitive 
analysis by flow cytometry (d). 
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Cells stained with cytokine-specific detection antibody for IL-5, IL13, IL-10 or IFN-γ, were 
further stained with anti-CD4 FITC and anti-CD14 PerCP antibodies in 100 µl of FACS buffer 
(1X PBS, 1% FBS, 0.1% sodium azide).  
Labeled cells were incubated for 20 minutes in the dark at 4°C and analyzed by flow cytometry.  
Before FACS analysis, 1 µl of Propidium Iodide (PI) (0.5 mg/ml, Sigma) was added to each 
sample to distinguish between live and dead cells. The dead cells and monocytes were excluded 
according to PI and CD14-PerCP staining.  
 
7. Immunophenotyping of CD4+ CD25++ cells  
PBMC from four allergic patients were cultured in RPMI complete medium with 10% FCS and 
seeded in 24 well tissue culture plate at a final concentration of 1 X 106 cells/ml.  
PBMC were incubated with the antigens, prepared as described before, at 10 µg/ml for 8 days at 
37°C and 5% CO2. The control sample was treated as the antigen-stimulated sample except for 
antigen addition. Cells were harvested every day, washed by adding 1 ml of cold FACS buffer  
and centrifuged at 1500 rpm for 5 minutes at 4°C; after centrifugation supernatant was pipetted off 
completely. 
PBMC were stained with anti-CD4 FITC and anti-CD25 PE.  
 
8. Immunophenotyping of CD4+ CD25++ CD127- T regulatory cells  
PBMC from five allergic patients were cultured as described in the previous paragraph. PBMC 
were incubated with the antigens, at 10 µg/ml, for 8 days at 37°C and 5% CO2. Cells were 
harvested at 6 days, 7 days and 8 days and washed by adding 1 ml of cold FACS buffer. 
PBMC were stained with anti-CD4 PerCP and anti-CD25 PE, anti-CD127 FITC. 
 
9. Immunophenotyping of CD4+ CD25++ GARP+ and CD4+ CD25++ LAP+ T regulatory cells 
PBMC from four allergic patients were cultured as previously described. PBMC were incubated 
with the antigens, at 10 µg/ml, for 3 days at 37°C and 5% CO2. Cells were harvested at 2hrs, 4hrs, 
6hrs, 18hrs, 1day, 2days and 3days and washed by adding 1 ml of cold FACS buffer. 




10. Multiparametric analysis of CD4+ CD25++ GARP+ LAP+ T regulatory cells 
PBMC from three allergic patients were cultured as previously described and were incubated with 
the antigens, at 10 µg/ml, for 6hrs. Cells were harvested at 2hrs and 6hrs and washed as prevoius 
described by adding 1 ml of cold FACS buffer. 
PBMC were stained with anti-CD4 PerCP and anti-CD25 FITC, anti-GARP APC and anti-LAP 
PE 
 
11. Immunophenotyping of CD4+ CD39+ GARP+ and CD4+ CD39+ LAP+ T regulatory cells. 
PBMC from two allergic patients were cultured and incubated as previously described for 8 days 
Cells were harvested for a short time course at 2hrs, 4hrs, 6hrs for a longer time course each day 
until day 8. Each time, PBMC were stained by adding anti-CD4 PerCP and anti-CD39 FITC, anti-
GARP PE or anti-LAP PE. 
 
12. Immunophenotyping of CD4+ CD25++ PD1+ cells  
PBMC from two allergic patients were cultured and incubated as previously described for 8 days 
Cells were harvested for a short time course at 2hrs, 4hrs, 6hrs for a longer time course each day 
until day 8. Each time, PBMC were stained by adding anti-CD4 PerCP and anti-CD25 FITC and 
anti-PD1 PE. 
 
13. CD4+CD25++ CD127- Tregs isolation from human PBMC 
The isolation of CD4+CD25++CD127- Tregs from human PBMC was performed following a two-
step procedure or sequential sorting: depletion followed by a positive selection. This strategy is 
useful for isolation of extremely rare cell population, which express CD4, CD25 with high 
intensity and does not express CD127. It can be useful first to deplete non-target cells, which 
express the same antigen used for successive positive selection of the target cells. Positive 
selection can then be carried out with the pre-enriched fraction to obtain a pure cell population. 
Therefore, during the first magnetic labeling, all non-CD4+ and CD127high cells were labeled with 
a cocktail of biotin-conjugated antibodies against CD8, CD14, CD16, CD19, CD36, CD56, 
CD123, TCR γ/δ and CD235a, as a primary labeling reagent. Then, these cells were magnetically 
labeled with anti-biotin monoclonal antibodies conjugated to Micro Beads, as a secondary labeling 
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reagent (Fig. 12 a). The labeled cells were 
subsequently depleted by separation over a LD 
MACS Column (Miltenyi Biotec), which was placed 
in the magnetic field of a MACS Separator (Miltenyi 
Biotec). The unlabeled cells pass through the column 
and therefore CD4+ T cells were collected as a 
negative fraction. Hence the first step allows the 
depletion of non-CD4+ cells (Fig. 12 b). In the second 
step, the CD4+ CD25++ CD127- Tregs are directly 
labeled with anti-CD25 antibodies conjugated to 
Micro Beads (Miltenyi Biotec). 
These were isolated by a positive selection from the 
pre-enriched CD4+ T cell fraction through separation 
over a MS MACS Column (Miltenyi Biotec), placed 
in a magnetic field (Fig. 12 c). 
The unlabeled CD4+ CD25- CD127 high T cells passed 
through the column and were collected as a negative 
fraction. After removing the column from the 
magnetic field, the magnetically retained 
CD4+CD25++CD127- Tregs were eluted as the 
positively selected cell fraction (Fig. 12 d). In 
particular, PBMC were isolated as described. PBMC 
from six were incubated with antigens, prepared as 
described at 10 µg/ml for 8 days. A negative control 
sample was treated as the antigen-stimulated sample 
but without the addition of antigen. After 8 days, the 
cells were collected and resuspended in 14 ml of 
HBSS supplemented with 1X penicillin/streptomycin. 
Cell suspension was centrifuged at 1,500 rpm for 10 
minutes at 4°C. After centrifugation, the cell pellet 
was resuspended in 90 µl of HBSS, supplemented 
with 1X penicillin/streptomycin. The cells were 
1st magnetic labeling  
Non-target cells are 
magnetically labeled with 
a biotinylated antibody 
cocktail and Anti-Biotin 
MicroBeads. 
 
1st magnetic separation 
Undesired cells are 
retained in a MACS 
Column placed in a 
MACS Separator while 
the unlabeled CD4+ 
CD127- cells pass 
through. 
 
2nd magnetic labeling 
The CD4+CD25++CD127- 
Tregs are magnetically 
labeled with MicroBeads. 
2nd magnetic separation 
Target cells are retained in 
the column while 
unlabeled cells pass 
through. 
After the column is 
removed from the 
separator, the target cells 
are eluted as the enriched, 
positively selected cell 
fraction. 
CD4+ CD127- CD25- CD4+ CD127- CD25++ 





Fig 12. Schematic representation Magnetic 
Sequential Sorting: two-step 
procedure, depletion followed by positive 
selection. 
1) Depletion of non-CD4+ T cells: After a long 
antigen specific restimulation PBMC are 
magnetically labeled (a) and labeled cells were 
subsequently depleted by separation over LD 
MACS Column (b). 
2) Positive selection of CD4+CD25++ cells: 
Indirect magnetic labeling of CD25++ cells with 
Anti-PE MicroBeads (c) and isolation on MS 
MACS Column (d). 
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subsequently labeled with 10 µl of CD4+ T Cell Biotin-Antibody Cocktail per 107 total cells. Each 
sample was mixed and incubated for 5 minutes on ice. After that, each sample was magnetically 
labeled with 20 µl of anti-biotin monoclonal antibodies conjugated to Micro Beads, mixed well 
and incubated for an additional 10 minutes on ice. After the magnetic labeling, 1ml of buffer were 
added to each cell suspension and proceeded to the magnetic separation. 
First of all, LD MACS Columns were placed in the magnetic field of MACS Separator and 
prepared by washing with 2 ml of HBSS buffer. After this step, the magnetic labeled cells were 
applied onto the column. The column was washed with 2 x 1 ml of HBSS buffer and unlabeled 
cells that passed through it were collected. These cells represented the unlabeled pre-enriched 
CD4+ cell fraction.  
In order to isolate CD4+CD25++CD127- Tregs from human PBMC, unlabeled pre-enriched CD4+ 
cell fraction was centrifuged at 1,500 rpm for 10 minutes at 4°C. After centrifugation, the cell 
pellet was resuspended in 90 µl of HBSS, and the cells were subsequently labeled with 10 µl of 
anti-CD25 Micro Beads. The magnetically labeled was processed as previously described and 
applied onto a MS MACS column. The column was washed with 3 x 0.5 ml of HBSS buffer and 
the unlabeled cells passed through the column and the flow-through contained the unlabeled CD4+ 
CD25- CD127high T cells. After that, 1 ml of HBSS buffer was applied onto the column, which was 
then removed from the magnetic separator, and the magnetically labeled CD4+CD25++CD127- 
cells were immediately flushed out by firmly pushing the plunger into the column. The purity of 
the enriched cell fractions was above 70%, as determined by flow cytometry. The two cell 
fractions were stained with anti-CD4 PerCP and anti-CD25 PE. 
 
14. TRIzol RNA extraction  
For further functional characterization the CD4+CD25++CD127- cell fraction obtained from six 
allergic patients were collected after magnetic separation and resuspended in 1 ml of TRIZOL 
Reagent. 
During sample homogenization or lysis, TRIZOL Reagent maintains the integrity of the RNA, 
while disrupting cells and dissolving cell components.  
The samples were centrifuged at 11,500 rpm for 10 minutes at 4°C to remove the cell debris and 
the supernatants were transferred into a new tube. Afterwards the samples were incubated for 5 
minutes at room temperature to leave complete dissociation of nucleoprotein complexes.   
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200 µl of chloroform per 1 ml of TRIZOL Reagent were added and each sample was mixed 
vigorously for 15 seconds and incubated at room temperature for 2 minutes. Afterwards the 
samples were centrifuged at 12,000 rpm for 5 minutes at 4°C to induce a phase separation where 
the proteins were extracted into lower red, phenol-chloroform phase, the DNA was extracted in an 
interphase and RNA remained in a colorless upper aqueous phase. 
After transferring the aqueous phase, the RNA was recovered by precipitation with 500 µl of 
isopropyl alcohol. The samples were incubated at room temperature for 10 minutes and than 
centrifuged at 12,000 rpm for 10 minutes at 4°C. The supernatant was removed completely and the 
pellet was washed with 1 ml of 75% ethanol at 9,000 rpm for 5 minutes at 4°C.  
The RNA pellet was resuspended in 10 µl of RNase-free water and stored at -80°C. RNA integrity 
is critical for a successful RNA quantitation; it was evaluated using a 1% agarose gel 
electrophoresis (data no shown). Concentration and purity of RNA were determined by measuring 
the absorbance in a spectrophotometer. The RNA concentration was determined by measuring the 
absorbance at 260 nm; an absorbance of 1 unit at 260 nm corresponds to 40 µg of RNA per ml. 
The ratio of the absorbance at 260 nm and 280 nm (A260/A280) provides an estimate of the purity 
of RNA with respect to contaminants. 
 
15. cDNA synthesis  
After RNA extraction from CD4+CD25++CD127- cell, the cDNA synthesis was performed using 
the QuantiTect Reverse Transcription cDNA kit according to the manufacturer's instructions 
(Quiagen). This kit provides a fast procedure for efficient transcription and effective genomic 
DNA elimination.  
Briefly, the reaction was performed with 1 µg total RNA, the purified RNA sample was incubated 
in 2 µl gDNA Wipeout Buffer 7X at 42°C for two minutes and then placed immediately on ice. 
This step allowed the genomic DNA elimination. The reverse transcription step was performed 
using a Master Mix prepared from 1 µl Quantiscript Reverse Transcriptase, 4 µl Quantiscript RT 
buffer 5X and 1 µl RT Primer Mix. The Master Mix was added to each RNA sample and the entire 
reaction was incubated at 42°C for 15 minutes and was then inactivated at 95°C for 3 minutes. 




16. Real Time-PCR 
Real-time PCR is a form of polymerase chain reaction (PCR) where the progress of reaction can 
be monitored as it occurs and allows to calculate the cDNA target quantity in a sample. To 
improve the characterization of CD4+CD25++CD127- Treg cells isolated as previously described, 
the cDNA obtained from six allergic patients was analyzed for the expression of FOXP3, IL-10, 
GARP and TGF-β1. cDNA expression for each sample was standardized using the 18S ribosomal 
RNA. 
Quantitative real time-PCR was performed in a STEP ONE PLUS (Applied Biosystems) using a 
Fast SYBR Green PCR kit (Applied Biosystems) and specific primers for the different analyzed 
target. PCR was carried out in 20 µl. 
 
For each sample the following mixture was prepared:  
• appropriate amount of cDNA, 
• 10µl FAST SYBR Green Master Mix (2x), 
• 0.2 µl  primers 10µM, 
• H2O to a final volume of 10 µl. 
 
 







18SrRNA Qiagen PPH05666E N/A X03205 100 1447 
FOXP3 Qiagen PPH00029C Hs.247700 NM_014009 89 2191 
IL-10 Qiagen PPH00572C Hs.193717 NM_000572 63 168 
GARP Qiagen PPH12836A Hs.151641 NM_005512 178 486 
TGF-β1 Qiagen PPH00508A Hs.645227 NM_000668 91 1477 
Table 2 – References of primers used for Real Time - PCR  
 
 
The relative changes in gene expression were analyzed by ΔΔC(t) method. Cycling conditions 
were: initialization 20 sec at 95°C followed by 40 cycles of 3 sec at 95°C and 30 sec at 60°C. 
After the cycling process, a melting curve analysis was performed to exclude unspecific PCR 
products and established the purity of the amplified genes.  
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The melting curve analysis (65°C to 95°C, step 0.5°C) reveals the presence of non specific 
annealing products as primer dimers and secondary non specific amplicon which can result from 
primer elongation or non specific annealing events.  
 
17. Satitistical analysis 
All the statistical analyses were performed using the StatView 5.0.1 software. A Wilcoxon test for 
comparisons between the two recruited groups was applied. Student’s paired t-test was used for 





In order to study the immunological mechanisms activated by the major allergens of Parietaria 
judaica, Par j 1 and Par j 2, and to investigate the differences between the wild type allergens and 
the hypoallergenic mutant rPjEDcys, the recombinant proteins were produced and were utilized to 
stimulate human Peripheral Blood Mononuclear Cells (PBMC) from Parietaria judaica allergic 
patients. Flow cytometry provides a better way to characterize cells of innate and adaptive immune 
system, based on morphological characterization (forward and side scatter) and on the expression 
of cellular markers. Therefore, staining of cells with antibodies has been used to identify, count 
and characterize different cell subset of PBMC from allergic patients, based on the expression of 
specific cell surface antigens. 
 
1. Production of recombinant proteins: rPar j1, rPar j 2 and rPjEDcys 
The recombinant proteins rPar j 1, rPar j 2 and rPjEDcys used in the following experiments were 
expressed as His-tagged proteins in E. coli and isolated by following different purification steps 
using various chromatographic techniques as described in "Materials and Methods”. 
Briefly, the recombinant allergens were first purified by affinity chromatography using His-Tag 
Columns and then eluted in a buffer containing imidazole. The total protein content was analyzed 
by the colorimetric Bio-Rad protein assay and aliquots from eluted fractions were analyzed by 
SDS-polyacrylamide gel and stained with the Coomassie Brilliant Blue dye. Gel analysis was 
performed using the image analysis system Chemidoc (Bio-Rad). The fractions containing 
recombinant proteins were diluted and purified in a second step of affinity chromatography 
followed by dialysis to dilute or remove urea from the samples. 
In order to completely remove the urea from the preparation and to allow a complete refolding of 
the proteins, the recombinant proteins were purified by affinity chromatography under no-
denaturing conditions. During a successive step, salts were removed from the fractions containing 
recombinant proteins and a gel filtration chromatography step was performed. Finally, in order to 
remove endotoxin from the recombinant protein preparations (all reagents used for cell culture 
have to be endotoxin-free), the fractions containing the highest concentration of recombinant 




The purified proteins were accurately quantified; the relative concentrations were measured using 












Recombinant proteins were tested for the endotoxin content using the multi-test lymulus 
amebocyte lysate (LAL) test. The endotoxin content in the wild-type allergens and hypoallergenic 
derivate rPjEDcys was less than 0.003 ng LPS/ µg of recombinant protein.  
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Fig. 14. Protein extracted from recombinant E. coli strains were analyzed by SDS-PAGE gel stained 
with Commassie Brillant blue. Lane 1: Novex Sharp Presteined Protein Standard, lane 2: rPar j 1, lane 3: 
rPar j 2, lane 4: rPjEDcys. 
 
Fig. 13. Proteins eluited from detoxi-gel coloumn were analyzed by SDS-PAGE gel stained with 
Commassie blue.  Lane 1: BSA 250 ng, lane 2: BSA 500 ng, lane 3: BSA 750 ng, lane 4: BSA 1000 ng; 
lanes 5-7: 3 µl, 4 µl and 5 µl of rPar j 1, lanes 8-10: 3 µl, 4 µl and 5 µl of rPar j 2; lanes 11-13: 3 µl, 4 µl 




2. Human PBMC proliferation assay: innate and adaptive immune response to Parietaria major 
allergens and the hypoallergenic derivate 
 
A recently published paper from Bonura et al. showed that rPjEDcys was able to stimulate CD3+ 
cellproliferation in allergic patients. Therefore, I wanted to investigate which cell subpopulation, 
within CD3+ cells, proliferated in response to the mixture of rPar j 1 and rPar j2 allergens and 
rPjEDcys hybrid. 
To do this, PBMC from 10 allergic patients to Parietaria judaica pollen were labeled with CFDA-
SE and cultured at 106 cells/ml without any antigenic stimulii (negative control) or with the 
following stimuli: a mixture of recombinant allergen Par j 1 and Par j 2 (1 and 10 µg/ml) or 
rPjEDcys (1 and 10 µg/ml). After 7 days of incubation cells were collected and stained. 
Initially, PBMC from the first 3 allergic patients were stained with anti-CD4 and anti-CD8. Our 
results have shown that rPjEDcys retains T cell reactivity, inducing a CD4+ proliferative response 
as the mixture of rPar j 1 and rPar j 2, but not CD8 proliferation.  However, particularly interesting 
data emerged by analyses on CD4- and CD8- proliferating cells.  
Although CD4- cells did not proliferate after antigen-specific stimulation, CD8- cells proliferated 
in response to the mixture of wild-type allergens and rPjEDcys hybrid. The role of the adaptive 
immune system in allergy has been well characterized but the role of the innate immune system in 
the development of allergies is a controversial area. Some papers describe how the innate immune 
system might contribute to the development of allergies [117-118]. Therefore, I wanted to 
investigate whether innate immune cells proliferate in response to the mixture of wild type 
allergens and to rPjEDcys. In order to do this, I decided to carry out a more detailed analysis that 
allowed me to characterize the CD8- proliferating cells, highlighting a CD8- proliferative response 
higher than CD4+ one. Therefore, in the other 7 allergic patients the staining was performed with 
anti-CD4, anti-CD8, anti-CD16 and anti-CD56. To study cell proliferation, analyzed cells were 
selected by a live lymphocyte gate based on the combination of forward (FSC) and side scatter 
(SSC) (data not shown). Background proliferation was measured in an unstimulated culture. In 
every experiment described in this thesis, we studied the immune response after antigen specific in 




2.1 Cytofluorimetric analysis on CD4+CFSE+ cells 
 
A detailed analysis on CD4+ cell proliferation in response to the mixture of allergens and rPjEDcys 
for a representative patient (patient 7) is shown in panels a-f of figure 15.  
PBMC stimulation with two different antigen doses of the mixture of Parietaria allergens, 1 and 
10 µg/ml, showed a dose-dependent increase of the percentage of CD4+ proliferating cells. The 
data reported in figure 15 also indicates that PBMC stimulation with rPjEDcys showed an increase 






















The data reported in figure 16 show the percentage of CD4+ proliferating cells in all the 10 P. 
judaica allergic patients after antigen-specific stimulation. 
 
Fig. 15. Representative dot plot of CD4+CFSE+ proliferation assay.  Panels show cytoflurimetric analyses 
on a representative patient (patient 7) Unstimulated CFSE-labeled PBMC (a.). CFSE-labeled PBMC 
stimulated with 1 and 10 µg/ml of a mixture containing the rPar j 1 and rPar j 2 allergens (b. and c.) and an 
equivalent concentration of rPjEDcys hybrid (e. and f.). CFSE-labeled PBMC stimulated with LPS (d.). 
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In 1 out of the 10 analyzed patients (patient 4), the mixture of wild-type allergens, used at 1 µg/ml, 
did not show a higher percentage of proliferating CD4+ cells than the unstimulated sample. 
However, in all the other analyzed patients, PBMC stimulation with the two different antigen 
doses of Par j 1 and Par j 2 allergens, showed a dose-dependent increase in the percentage of CD4+ 
proliferating cells. All patients, except one (patient 6), showed an increase in percentage of 
proliferating CD4+ cells in response to rPjEDcys. In five out ten patients (patients 1-5) the 
percentage of CD4+ proliferating cells in response to rPjEDcys is higher when used at lower 
concentration. 
 
2.2 Cytofluorimetric analysis on CD8+CFSE+ cells 
 
Analyses about the CD8+ cell proliferative response to the mixture or the hypoallergenic hybrid, 
are shown in panels a-f of figure 17. This representative experiment (patient 7) highlighted that 






Fig. 16. Histograms of percentage of CD4+ Proliferating cells. Histogram and table show the percentage of 
CD4+ proliferating cells in response to the mixture of allergens and rPjEDcys. The values were subtracted 
of the proliferation obtained in the unstimulated culture. 

































The data reported in figure 18 show the percentage of CD8+ proliferating cells in all the 10 P. 









Fig. 17.  Representative dot plot of CD8+CFSE+proliferation assay. Panels show cytoflurimetric 
analyses on a representative patient (patient 7) Unstimulated CFSE-labeled PBMC (a.). CFSE-labeled 
PBMC stimulated with 1 and 10 µg/ml of a mixture containing the rPar j 1 and rPar j 2 allergens (b. and 
c.) and an equivalent concentration of rPjEDcys hybrid (e. and f.). CFSE-labeled PBMC stimulated with 
LPS (d.). Background proliferation was measured in unstimulated culture. 
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Fig. 18. Histograms of percentage of CD8+ Proliferating cells. Histogram and table show the percentage of 
CD8+ proliferating cells in response to the mixture of allergens and rPjEDcys. The values were subtracted of 
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2.3 Cytofluorimetric analysis on CD16+CFSE+ cells 
 
Our data showed that other cells, not phenotypically characterized, proliferated in response to the 
mixture of Parietaria allergens and rPjEDcys hybrid. Therefore, I wanted to investigate which 
other cell subpopulation proliferated after the in vitro stimulation with different antigen doses of 
the rPar j 1 and rPar j 2 allergens and an equivalent concentration of the rPjEDcys hybrid. 
I proposed to study the innate immune cell response to Parietaria major allergens and 
hypoallergenic derivate. In order to do this, PBMC were also stained with labeled antibodies 
against CD16 or CD56 (NK cell markers).  
Panels a-f of figure 19 show a more detailed analysis on CD16+ cell proliferation in response to the 
mixture of allergens and to rPjEDcys for a representative patient (patient 7). Staining with anti-
CD16 and cytofluorimetric analyses showed that CD16+ cells did not proliferate in response to the 



















Fig. 19.  Representative dot plot of CD16+CFSE+proliferation assay. Panels show cytoflurimetric analyses 
on a representative patient (patient 7) Unstimulated CFSE-labeled PBMC (a.). CFSE-labeled PBMC 
stimulated with 1 and 10 µg/ml of a mixture containing the rPar j 1 and rPar j 2 allergens (b. and c.) and an 
equivalent concentration of rPjEDcys hybrid (e. and f.). CFSE-labeled PBMC stimulated with LPS (d.). 
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The data reported in figure 20, show the percentage in CD16+ proliferating cells in 7 allergic 
patients (from patient 3 to 10) after antigen-specific stimulation. Our analyses demonstrated that 













2.4 Cytofluorimetric analysis on CD56+CFSE+ cells 
 
A detailed analysis on CD56+ cell proliferation in response to the mixture of allergens and 
rPjEDcys for a representative patient (patient 7) is shown in panels a-f of figure 21. Cell staining 
with anti-CD56 and cytofluorimetric analyses showed that allergen stimulation resulted in an low 
increase in percentage of CD56+ cells. The data reported in the panels of figure 21 indicates that 
PBMC stimulation with the two different antigen doses of the mixture induced a dose-dependent 
increase in percentage of CD56+ proliferating cells compared to an unstimulated cells. Moreover, 
also PBMC stimulation with rPjEDcys hybrid showed a dose-dependent increase in percentage of 
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Fig. 20. Histograms of percentage of CD56+ proliferating cells. Histograms show the percentage of 
CD56+ proliferating cells in response to the mixture of allergens and rPjEDcys subtracted of the 























The data reported in figure 22, show the percentage in CD56+ proliferating cells in 7 allergic 
patients (from patient 3 to 10). These data demostrate CD56+ cells proliferated after the stimulation 
with the mixture of allergens and to the hypoallergenic hybrid in a dose dependent manner even 











Fig. 21. Representative dot plot of CD56+CFSE+proliferation assay. Panels show cytoflurimetric analyses 
on representative patient (patient 7) Unstimulated CFSE-labeled PBMC (a.). CFSE-labeled PBMC 
stimulated with 1 and 10 µg/ml of a mixture containing the rPar j 1 and rPar j 2 allergens (b. and c.) and an 
equivalent concentration of rPjEDcys hybrid (e. and f.). CFSE-labeled PBMC stimulated with LPS (d.). 
Background proliferation was measured in unstimulated culture.  
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Fig. 22. Histograms of percentage of CD56+ proliferating cells. Histograms show the percentage of CD56+ 
proliferating cells in response to the mixture of allergens and rPjEDcys subtracted of the proliferation obtained 
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PBMC proliferation assays showed that CD4+ cells are clearly the major cell population 
proliferating in response to the mixture of wild-type allergens and to the rPjEDcys. Moreover, 
these studies, combined with other experimental data, showed that the mixture of allergens and 
rPjEDcys hybrid are able to induce proliferation of CD56+ cells and suggested that innate immune 
cells are associated with allergic response. 
 
3. IL-5, IL-13, IL-10 and IFN-γ cytokine secretion assay after PBMC stimulation with wild type 
allergens and rPjEDcys 
 
Our results showed that CD4+ cells are the main proliferating cell population in response to the 
mixture of Par j 1 and Par j 2 allergens. Furthermore, the hypoallergenic derivate rPjEDcys 
retained the ability to stimulate CD4+ cell proliferation. The recognition of antigens by memory 
CD4+ T cells initiates an immunological response characterized by the rapid secretion of several 
different cytokines. Therefore, I decided to study the cytokine production by CD4+ T cells after an 
antigen-specific in vitro stimulation.  
I was interested in analyzing four different cytokines released by PBMC of allergic patients, in 
response to the mixture of wild type allergens and to the rPjEDcys hybrid. 
I set up an experimental design that could allow me to investigate if there were any differences 
regarding the Th1/Th2 profile induced by rPjEDcys hybrid in comparison to the wild type 
allergens. In particular, I decided to look at some of the most important inflammatory and 
regulatory cytokines such as IL-5 and IL-13, which are Th2 cytokines that play a critical role in 
the development of allergy. IFN-γ, the main Th1 effector cytokine, and IL-10 which is an 
important cytokine with anti-inflammatory and suppressive functions. 
To accomplish this experimental design, I chose to carry out a cytokine secretion assay.  
PBMC from 10 allergic patients were stimulated in vitro for 16 hrs with a mixture of wild type 
allergens and rPjEDcys hybrid at the final concentration of 20 µg/ml. The co-stimulatory 
antibodies (anti-CD28/49d) were added in all samples to enhance the T cell response. A negative 
control sample was treated exactly the same as the antigen-stimulated sample but without the 
addition of antigen; this control was included to evaluate the spontaneous cytokine secretion. 
The cytokine secreting cells were stained with anti-CD4 and dead cells were excluded by staining 
with propidium iodide (PI), to reduce nonspecific background staining and increased sensitivity. 
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Moreover, for an optimal sensitivity I labeled monocytes with anti-CD14. 
Therefore, analyzed cells were selected by a lymphocyte gate (R1) based on the combination of 
FSC and SSC (as shown in Fig. 23 A). An R2 gate selected cytokine-secreting cells, excluding 
dead cells and monocytes in accordance to PI and CD14 staining in a FL-2-cytokine versus an FL-












Panels of figures 24-27 show data for a representative experiment (patient 10) of 10 analyzed 
patients. Background cytokine secretion by CD4+ cells was measured in an unstimulated culture. 
IL-5 secretion assay showed that PBMC stimulation with the mixture of wild type allergens or 
rPjEDcys hybrid induced an increase in IL-5 secreting allergen-specific T CD4+ cells of 22.1% 













Fig. 23. Detection and isolation of cytokines secreting cells. A. Cells were selected by a lymphocyte gate based 
on the combination of forward (FSC) and side scatter (SSC) B. Cytokine secreting cells were selected by R2 gate 


































Fig. 24. Representative dot plot of IL-5 Secretion Assay. IL-5 secreting allergen-specific T CD4+cell for a 
representative patient (patient 10) in unstimuleted culture (a) and after a stimulation with a mixture containing the 
rPar j 1 and rPar j 2 allergens (b) and an equivalent concentration of rPjEDcys hybrid (c). Inside of dot plot b. and c. 
it is shown the difference between the percentage of IL-5 secreting T CD4+ cell after antigen-specific stimulation 
and the unstimulated culture. 
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Panels of figure 25 show the percentage of IL-13 secreting T CD4+ cells in patient 10.  IL-13 
secretion assay showed the mixture of wild type allergens induced an increase in percentage of IL-
13 secreting T CD4+ cells of 9%, instead rPjEDcys hybrid did not induce an increase of IL-13 














Staining with anti-IFN-γ and following flow cytometric analysis, showed that CD4+ cell did not 
produce IFN-γ after stimulation with the mixture. On the contrary, this analysis showed that 
rPjEDcys hybrid induced a low increase of IFN-γ secreting T CD4+ cells of 0.6% (panels a-c of 
















Fig. 26. Representative dot plot of IFN- γ Secretion Assay. IFN-γ secreting allergen-specific T CD4+cell for a 
representative patient (patient 10) in unstimuleted culture (a) and after a stimulation with a mixture containing 
the rPar j 1 and rPar j 2 allergens (b) and an equivalent concentration of rPjEDcys hybrid (c). Inside of dot plot b. 
and c. it is shown the difference between the percentage of IFN-γ secreting T CD4+ cell after antigen-specific 
stimulation and the unstimulated culture. 
Fig. 25. Representative dot plot of IL-13 Secretion Assay. IL-13 secreting allergen-specific T CD4+cell for a 
representative patient (patient 10) in unstimuleted culture (a) and after a stimulation with a mixture containing the 
rPar j 1 and rPar j 2 allergens (b) and an equivalent concentration of rPjEDcys hybrid (c). Inside of dot plot b. and c. it 
is shown the difference between the percentage of IL-13 secreting T CD4+ cell after antigen-specific stimulation and 
the unstimulated culture. 
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Finally, the IL-10 secretion assay, for this representative experiment (patient 10), showed that only 
PBMC stimulation with the mixture of wild type allergens induced an increased percentage of IL-

















A cytofluorimetric analysis using PBMC from this P. judaica allergic patient (patient 10) showed 
that PBMC stimulation with the hypoallergen induced a lower IL-5 and IL-13 secretion by CD4+ 
cells compared to the mixture. As regards the IFN-γ secretion, our cytofluorimetric analysis have 
shown that IFN-γ secretion by CD4+ cells did not increase in response to the mixture of Parietaria 
allergens, however a low increase of IFN-γ secreting T CD4+ cells was observed in response to 
rPjEDcys hybrid. Moreover, the analyses on patient 10 have indicated that only PBMC stimulation 
with the mixture induced an increased production of suppressive cytokine IL-10 by T CD4+ cells 
(2.5%).  
The data reported in panels A-D of figure 28 show the results of the cytokine secretion assay for 
each cytokines studied. Each panel shows the percentage of cytokine-secreting CD4+ cell for 10 P. 
judaica allergic patients after antigen-specific stimulation subtracted of the cytokine background 
in the unstimulated culture. 
 
 
Fig. 27. Representative dot plot of IL-10 Secretion Assay. IL-10 secreting allergen-specific T CD4+cell for a 
representative patient (patient 10) in unstimuleted culture (a) and after a stimulation with a mixture containing 
the rPar j 1 and rPar j 2 allergens (b) and an equivalent concentration of rPjEDcys hybrid (c). Inside of dot plot 
b. and c. it is shown the difference between the percentage of IL- secreting T CD4+ cell after antigen-specific 
stimulation and the unstimulated culture. 



































These results pointed out that in all 10 studied patients, PBMC stimulation with the mixture or 
with rPjEDcys hybrid showed some differences concerning the cytokine profile produced by CD4+ 
T cells. 
In eight out of ten analyzed patients (patients 1-5, 8-10) PBMC stimulation with the mixture of 
allergens showed an increase in the percentage of IL-5 secreting CD4+ cells. In five out of ten 
analyzed patients (patients 1-3, 8-10) PBMC stimulation with rPjEDcys showed an increase in the 
percentage of IL-5 secreting CD4+ cells, but it is generally lower than that induced by the mixture. 
While patients 6 and 7 did not show an increase in IL-5 secreting T CD4+ cells after the in vitro 
stimulation with the two different antigens. These patients showed a generally weak cytokine 
secretion by CD4+ cells (Fig. 28 A). Panel B of figure 28, shows the percentage of IL-13 secreting 
T CD4+ cells in all ten patients. In nine out of ten analyzed patients (all patients except number 3), 
Fig. 28. Histograms show the percentage of cytokines secreting antigen-specific T CD4+ cells. Percentage of 
cytokine- secreting T CD4+ cells in response to the mixture of allergens and rPjEDcys subtracted of cytokines 
background obtained in the unstimulated culture. IL-5 secreting T CD4+ cells are showed in panel A, IL-13 
secreting T CD4+ cells are showed in panel B, IFN-γ secreting T CD4+ cells are showed in panel C, IL-10 




% Cytokine-secreting CD4+ cells 
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PBMC stimulation with the mixture of wild type allergens induces an increase in percentage of IL-
13 secreting T CD4+ cells. In five out of ten analyzed patients (patients 1, 2, 4, 5 and 9), also 
PBMC stimulation with rPjEDcys increases the secretion of IL-13 by CD4+ cells, which is less 
pronounced than that induced by the mixture.  
In summary, these cytokine secretion assays have shown that PBMC in vitro stimulation with 
rPjEDcys induces a lower secretion of IL-5 and IL-13 by T CD4+ cells than the wild type 
allergens. These results are very interesting because IL-5 and IL-13 are Th2 cytokines with a 
critical role in the development of allergy and actually many studies identify them as a primary 
therapeutic target for the improvement of allergic symptoms [63-66]. 
Differences between the cytokine secretion in response to the mixture and PjEDcys were tested 














Published data showed that allergen specific-immunotherapy induces an immune deviation in T 
helper cytokine phenotype from Th2 towards a protective Th1 response and triggers a tolerogenic 
response. Sure enough, SIT treated patients revealed increases in IFN-γ expressing cells.  
Therefore IFN-γ and IL-10 secretion by CD4+ cells was investigated. These cytokines are 
particularly relevant since they may represent a redirection of the allergen-specific Th2 response 
towards a protective Th1 immune response and establish an allergen-specific immune tolerance. 
They can produce cascades, enhance or suppress the production of each other and often influence 
their actions [119-122].  
Fig. 29. Cytokine secretion in total patients. Comparison of % IL-5(A)- and IL-13 (B)-secreting CD4+ cells 
from PBMC cultures stimulated with the mixture of wild type allergens and PjEDcys. Statistically significant are 




Our analysis on IFN-γ and IL-10 secretion assays were performed only on cytokines-secreting 
CD4+ cells and showed a high individual variability. CD4+ cells are not the only source of IFN-γ 
and IL-10 and it would be interesting to perform further analyses in order to study IFN-γ and IL-
10 secretion in response to Parietaria allergens and hypoallergenic derivate.  
It is known that a wide range of cellular types produce IFN-γ and IL-10. IFN-γ is the main 
cytokine produced by Th1 cells but these cells are not the only source of IFN-γ. Several studies 
have identified additional IFN-γ secreting cell types, including activated Natural Killer (NK) cells, 
CD8+ T cytotoxic cells γδ T cells, NKT cells, macrophages, dendritic cells and B cells. 
 IFN-γ is known to be a pleiotropic cytokine that induces and modulates many different immune 
responses, it also exerts a suppressive effect on allergic disease by various mechanism one of 
which is by direct inhibitory effects on Th2 cytokines, reducing the levels of IL-4, IL-5 and IL-13 
production. Many different cell populations can produce IL-10, depending on stimulation and 
environmental conditions.  
T CD4+ cells could mediate their suppressive activity by secreting a high level of  IL-10.  
Additional IL-10-secreting cell types have been identified as monocyte, NK cells, DC and B cells. 
Starting from the awareness that some cytokines could be produced by many cell types and 
besides one cytokine often influences the synthesis of other ones, I decided to look at IFN-γ and 
IL-10 production by CD4- T cells especially on the patients 6, 7 and 9, who had not shown an 
increase in percentage of cytokine-secreting CD4+ cells. The data reported in panels of figure 29 
show the results of cytokine secretion assay for IFN-γ and IL-10 in one out of these three patients 
(patient 7).  
Panels a-c of figure 30 show the results of IFN-γ secretion assay, while panels d-f show the results 























Our analyses on patient 7 have shown that in vitro stimulation with the mixture or rPjEDcys 
induced a high increase in IFN-γ secreting CD4- cells, of 21.1% and 25.3% respectively. In 
addition, the percentage of IL-10 secreting CD4- cells increased of 8.7% and 2.5% in response to 
the mixture and rPjEDcys respectively. 
The data reported in panels A-B of figure 31 show the results of the cytokine secretion assay for 
IFN-γ and IL-10 by CD4- cells in patients 6, 7 and 9.  
  
Fig 30. Representative dot plot of IFN-γ and IL-10 Secretion Assay on CD4- cells. INF-γ secretion 
assay (a-c) and IL-10 secretion assay (d-f) for a representative patient (patient 7) in unstimuleted culture 
(a and d) and after a stimulation with a mixture containing the rPar j 1 and rPar j 2 allergens (b and e) and 
an equivalent concentration of rPjEDcys hybrid (c and f). Inside of dot plot b. and c. it is shown the 
difference between the percentage of IL-10 secreting T CD4- cell after antigen-specific stimulation and 
the unstimulated culture. 
a. b. c. 






























Cytofluorimetric analysis on CD4- cells allowed us to investigate further the immunological 
response activated after the in vitro stimulation with the mixture of wild type allergens and 
hypoallergenic hybrid.  
The analyses on patient 6, 7 and 9 suggested that presumably the missed or low IL-5 and/or IL-13 
secretion by CD4+ cells after the in vitro stimulation with the mixture of wild type allergens could 
be due to an increase in production of IFN-γ and/or IL-10 by different cells, some of which did not 
express CD4 on their cell surface. The identity of these cells remained unknown and it would be 
interesting characterize them. Surely, other studies have to be performed to further investigate the 
role of these cytokines in the immune response both to the mixture of Parietaria major allergens 
and rPjEDcys. 
 
4. Modulation of CD25 expression on CD4+ cells in response to Parietaria major allergens and 
rPjEDcys 
 
During recent years there was increasing evidence on the development of allergy, as a mechanism 
controlled by several populations of Tregs. Studies on immune response to allergens in healthy 
non-atopic individuals showed that Tregs play a crucial role in preventing Th2 response to 
allergens and in maintaining the peripheral tolerance.  
Fig. 31. Histograms of percentage of INF-γ and IL-10 secreting antigen-specific T CD4- cells. 
Percentage of cytokine- secreting T CD4- cells in response to the mixture of allergens and rPjEDcys 
subtracted of cytokines background obtained in the unstimulated culture. IFN-γ secreting T CD4- cells are 
showed in panel A and IL-10 secreting T CD4- cells are showed in panel B.  
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It is accepted that Tregs play their role during the sensitization phase, and therefore the targeting 
of Tregs could be an advantageous therapy for the prevention and/or treatment of pathogenesis of 
allergy [81].  
In order to study the selection of a putative allergen-specific subset of Tregs, I evaluated the 
modulation of CD4 and CD25 expression on PBMC from allergic patients by means of 
immunophenotyping.  
CD25 is the interleukin-2–receptor a-chain that is expressed by Tregs and also by activated 
effector T cells. Nevertheless, the density of CD25 expression allows the distinction between 
regulatory and activated effector T cells. 
PBMC isolated from heparinized peripheral blood from 4 allergic patients were stimulated for a 
time course of 8 days valuated each day for the expression of CD4 and CD25 by multiparametric 
flow cytometry (see Materials and Methods). 
Therefore, analyzed cells were selected by a live lymphocyte gate based on the combination of 
FSC and SSC. 

















































Fig. 32. Representative flow cytometric Dot Plot analysis of CD4+ CD25++ cells. PBMC from a 
representative allergic patient (patient 4) were cultured with the mixture of wild type allergens (b) and 
hypoallergenic hybrid (c) for 8 days. (a):  negative control. Numbers inside the graphs indicate the 


































From these analyses we observed that CD4+CD25++ population started to increase from day 6 and 
reached its peak at day 8 after the in vitro stimulation. These analyses highlight that PBMC 
stimulation with the mixture of wild type allergens or rPjEDcys modulate the CD25 expression on  
CD4+ cell surface. 
This pattern of activation was observed in almost all analyzed patients with some differences 
during the time course of stimulation (Fig. 33). The pattern of activation reached the peak between 















5. Study of allergen-specific CD4+ CD25++ CD127- Tregs after PBMC stimulation with 
Parietaria major allergens and hypoallergenic hybrid 
 
As previously shown PBMC stimulation with the mixture of wild type allergens rPar j 1 and rPar j 
2 and the rPjEDcys hybrid for a time course of 8 days induced an increase in CD4+CD25++ cells 
from day 6 and this population reached its peak on day 7 or 8. 
Fig. 33. Histograms of percentage of CD4+CD25++. Graphic show the percentage of activated CD4+CD25++ 
cells after in vitro stimulation with the mixture of wild type allergens and rPjEDcys, subtracted of the 
background in the unstimulated culture. 
 a   b 
  d c 
 66 
 
Starting from these preliminary data, we wanted to further investigate whether an allergen-specific 
Treg subset was activated after the in vitro stimulation with the mixture of wild type allergens or 
the hybrid. Different regulatory cell subsets have been described and the best characterized in 
pathology of allergic disease are CD4+CD25++ CD127- Tregs. These cells are characterized by the 
constitutive expression of high levels of CD25 (IL-2 receptor α chain) and the low or no 
expression of CD127 [80-81].  
Although CD4 and CD25 identify a Tregs subset, activated effector T cells also express the two 
antigens. Nevertheless, the density of CD25 expression allows us to discriminate between human 
regulatory and activated effector T cells, but other markers may be helpful in this discrimination. 
CD127, the α-chain of the IL-7 receptor, is expressed on most mature T cells and plays an 
important role in their proliferation and differentiation. CD127 is absent on Tregs, thus CD127 can 
be used as an additional marker to discriminate between Tregs and activated effector T cells [123-
124]. In order to characterize whether an allergen-specific Tregs subset was activated after the in 
vitro stimulation with the mixture of wild type allergens or the rPjEDcys hybrid, PBMC from six 
allergic patients were cultured in presence of 10 µg/ml of antigens for 8 days and analyzed looking 
at two outputs:  
- Immunophenotyping experiment: PBMC were analyzed at day 6, 7 and 8 for the expression of 
CD4, CD25 and CD127 by flow cytometry. 
- Tregs isolation and characterization: PBMC at day 8 were magnetically labeled for the isolation 
of CD4+CD25++CD127-.  
Therefore, cells were selected by a live lymphocyte gate (R1) based on the combination of FSC 
and SSC (as shown in Fig. 34 A) and were selected also by a R2 gate based on the expression of 





















Fig. 34. Gating strategy: A. Dot plot of forward scatter (FSC) versus side scatter (SSC), analyzed cells 
were selected by a lymphocyte gate based on the combination FSC and SSC B. Dot plots of CD4 versus 




























These analyses highlight that PBMC stimulation with the mixture of wild type allergens or 
rPjEDcys activated CD4+ CD25++ cells. Moreover, these cells express high level of CD25 (data not 
shown) but not CD127 on their cell surface.  
Our analysis on patient 5 have shown that the stimulation with a mixture of rPar j 1 and rPar j 2 
allergens induced an increase in the percentage of activated CD4+CD25++ CD127-, after 6, 7 and 8 
days in culture, of 4.4%, 2.6% and 3.9% respectively. This increase is more significative after the 
in vitro stimulation with rPjEDcys. In fact, the hypoallergenic derivate induced an increase in the 
percentage of activated CD4+CD25++CD127- of 4.9%, 18.4% and 6.7%, at 6, 7 and 8 days 
Fig. 35 Representative flow cytometric Dot Plot analysis of CD4+ CD25++ CD127- cells. PBMC from an 
allergic patient (patient 5) were cultured with the mixture of wild type allergens and hypoallergenic hybrid for 
8 days. Numbers inside the graphs indicate the percentage of CD4+CD25++ CD127- cells substracted of the 
















respectively. In this representative patient, the percentage of CD4+ CD25++ CD127- cells reached 
its peak on day 6 in response to the mixture and on day 7 in response to rPjEDcys. Moreover, the 
hypoallergen induced a more significative increase in the percentage of activated 
CD4+CD25++CD127- compared to the mixture of wild type allergens. These results suggested the 
activation of Treg subsets in response to the mixture of rPar j 1 and rPar j 2 and hypoallergenic 
hybrid. The data reported in panels A-E of figure 36 show the results of the immunophenotyping 





























In these experimental settings, we were able to demonstrate that PBMC stimulation with the 
mixture of wild type allergens and the rPjEDcys induced the activation of a putative subset of 
Tregs, defined as CD4+CD25++ CD127-. Our analyses showed that PBMC stimulation with the 
Fig. 36. Histograms show the percentage of 
CD4+CD25++CD127-. CD4+CD25++CD127- T cells 
form 5 allergic patients (A-E) induced by PBMC 
stimulation with the mixture of w.t. allergens and 
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rPjEDcys induce a generally more significative increase in percentage of CD4+CD25++ CD127- T 
cells compared to the mixture. 
These results strongly suggested the activation of Treg subsets by hypoallergenic hybrid. 
 
6. Magnetic separation of CD4+ CD25++ CD127- Tregs after stimulation with Parietaria major 
allergens and hypoallergenic hybrid 
 
To further characterize putative Treg subset activate in response to the mixture of wild type 
allergens and rPjEDcys PBMC from six allergic patients were cultured for 8 days and 
magnetically labeled for the isolation of CD4+CD25++CD127- (Tregs).  
The magnetic activated cell sorting was used in order to isolate CD4+CD25++CD127- Tregs and to 
perform a phenotypic and molecular characterization. The isolation of CD4+CD25++CD127- Tregs 
from human PBMC was performed using a two-step magnetic purification MACS procedure. The 
method can be divided into three phases and each phase has its own results. 
1) Before magnetic separations, the PBMC were evaluated for the expression of CD4 and CD25 
by multiparametric flow cytometry. [Analysis gate was set on live lymphocyte gate based on the 
combination of FSC and SSC]. Our analysis showed that the in vitro stimulation with the mixture 
of Parietaria major allergens and the hypoallergenic hybrid induced an increase of CD4+ CD25+ 











Fig. 37. Flow cytometric analysis on CD4+ CD25++ cells. PBMC from Parietaria allergic patient were cultured 
with the mixture of wild type allergens (b) and hypoallergenic hybrid (c) for 8 days. A negative control sample 
was treated as the antigen-stimulated sample but without addition of antigen (a). Cells were collected after 8 
days and before magnetic separation these cells were labeled with an anti-CD4 and anti-CD25 mAbs and 
analyzed by flow cytometry. Numbers inside the graphs indicate the percentage of CD4+ CD25++ cells compared 
to an unstimulated culture. 
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2) With the aim of enriching for CD4+ T cells expressing high levels of CD25, the remaining part 
of the samples was magnetically labeled and isolated using two consecutive enrichment steps. 
During the first magnetic purification, all PBMC were labeled with a cocktail of biotin-conjugated 
antibodies that allowed the labeling of all PBMC except for CD4+CD127- cells. Then, PBMC were 
indirectly magnetically labeled with anti-biotin monoclonal antibodies conjugated to Micro Beads, 
as secondary labeling reagent. 
The magnetically labeled cell suspension was loaded onto a LD MACS column, which was placed 
into the magnetic field of a MACS Separator. Therefore, non-CD4+ T cells were retained in the 
column, while the unlabeled, CD4+ CD127- T cells flowed through and were collected (negatively 
selected cell fraction). Then, columns were removed from the magnetic field and the retained non-
CD4+ T cells were eluted and collected (the positively selected cell fraction).  
An aliquot of each positively and negatively selected cell fraction was fluorescently stained with 
anti-CD4 and anti-CD25 antibodies. These samples were analyzed for the CD4 and CD25 
expression, in order to evaluate the percentage of enrichment and/or depletion of the different cell 
populations. Figure 38 shows the two fractions obtained after the first magnetic separation: the 
magnetically labeled fraction, containing the non-CD4+ cells and the flow-through fraction, 
















Depletion of non-CD4+ cells with LD Column 
from total PBMC 
Fig. 38. Schematic representation of depletion of non-CD4+ cells. The first of the two-steps of magnetic 
purification allows to obtain two different fractions: the magnetically labeled fraction containing the non-CD4+ 
cells and the flow-through fraction containing the pre-enriched CD4+ CD127- cells. During the depletion phase, 
undesired cells (all non- CD4+ cells) are retained in a MACS column and are eluted after removing the column 
from the magnetic separator while the unlabeled cells pass through the MACS column and collected as pre-
enriched fraction. 
non-CD4+ cells (magnetically 
labeled fraction) 










The data reported within figure 39 show the cytometric analysis performed on the two fractions 
obtained from the first magnetic separation, showing that, in all three analyzed samples, an 





























Fig. 39. Flow cytometric Dot Plot analysis of CD4+ CD25++ cells. Cytometric analysis was performed on 
the two fractions obtained from the first magnetic separation: 1) magnetically labeled fraction containing 
the non-CD4+ cells in unstimuleted culture (a) and after in vitro stimulation with a mixture containing the 
rPar j 1 and rPar j 2 allergens (b) and an equivalent concentration of rPjEDcys hybrid (c) 2) the flow-
through fraction containing the pre-enriched CD4+ CD127- cells in unstimuleted culture (d) and after in 
vitro stimulation with a mixture containing the rPar j 1 and rPar j 2 allergens (e) and an equivalent 
concentration of rPjEDcys hybrid (f). Numbers inside the graphs indicate the percentage of CD4+ CD25++ 
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3) The third phase of the experiment allows the selection of CD4+CD25++CD127- Tregs based on 
the intensity of fluorescence of the surface molecule CD25.  
Pre-enriched CD4+CD127- cell fractions (flowed-through fractions obtained from the first 
magnetic separation) were magnetically labeled with anti-CD25 Micro Beads.  
In this second step, the CD4+CD25++CD127- Tregs were isolated by a positive selection from the 
pre-enriched CD4+CD127- T cell fraction by means of the separation over a MS MACS Column, 
which was placed into the magnetic field of a MACS Separator.  
Figure 40 shows the two fractions obtained after the second magnetic separation: the magnetically 
labeled fraction containing the enriched CD4+ CD25++ CD127- cells and the flow-through fraction 


















Therefore, during this second purification, target cells (magnetically labeled CD4+CD25++CD127- 
T cells) were retained in the column and the unlabeled CD4+CD25- CD127- T cells run through 
and were collected as the negatively selected cell fraction. After removing the column from the 
Positive selection of CD4+ CD25++ CD127- regulatory T cells with MS 
Columns from pre-enriched CD4+ CD127- fraction 
Fig. 40. Schematic representation of positive selection. The second step of magnetic purification allows 
two obtain two different fractions: the magnetically labeled fraction, containing the enriched 
CD4+CD25++CD127- cells, and the flow-through fraction, containing the CD4+ CD25- CD127- cells. During 
the positive selection phase, target cells are retained in the MACS column and are eluted after removing the 
column from the magnetic separator, while the unlabeled cells pass through the MACS column and are 








Enriched CD4+CD25++CD127- cells 
(magnetically labeled fraction) 
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magnetic field, the magnetically retained CD4+CD25++CD127- Tregs were eluted as the positively 
selected cell fraction.  
In order to evaluate the percentage of enrichment and/or depletion of the different cell populations, 
aliquots of the positively and of the negatively selected cell fractions were fluorescently stained 
with anti-CD4 and anti-CD25 antibodies and analyzed for the expression of the two cell surface 
antigens.   
The second step of magnetic separation allowed us to remove the non-CD4+ cells still present in 
the pre-enrichment fraction and allowed us to further enrich the CD4+ population in all samples. 
As expected, the percentage of CD4+CD25++CD127- purified in each sample was very low, 
because antigen-specific Tregs are very rare. 
Figure 41 shows the cytofluorimetric analysis performed on the two fractions obtained from the 
second magnetic separation: the magnetically labeled fraction containing the enriched 
CD4+CD25++CD127- Tregs and the flowed-through fraction containing the CD4+CD25- CD127- 
cells. 
These data have shown that in an unstimulated samples, 1% of cells retained in the column and 
eluted as positive fraction were CD4+CD25++ cells (panel a), but some of these cells identified as 
CD4+CD25++ passed through the column and were collected in the negative fraction: these 
represent 0.4% of harvested cells (panel d).  
In samples stimulated with the mixture of Parietaria major allergens, 2.9% of the cells retained in 
the column and eluted as positive fraction were the CD4+CD25++ cells, (panel b) although 2.3% of 
the cells collected in negative fraction were the CD4+CD25++ cells (panel e). 
In the samples stimulated with rPjEDcys, 2.7% of the cells retained in the column and eluted as 
positive fraction were CD4+CD25++ cells (panel c), while 0.8% of the cells that passed through the 


































Fig 41. Flow cytometric analysis on CD4+ CD25++ cells. Cytofluorimetric analysis was performed on the 
two fractions obtained from the first magnetic separation: 1) magnetically labeled fraction containing the 
CD4+ CD25++ CD127- cells in unstimuleted culture (a) and after in vitro stimulation with a mixture 
containing the rPar j 1 and rPar j 2 allergens (b) and an equivalent concentration of rPjEDcys hybrid (c) 2) 
the flow-through fraction containing the CD4+ CD25- CD127- cells in unstimuleted culture (d) and after in 
vitro stimulation with a mixture containing the rPar j 1 and rPar j 2 allergens (e) and an equivalent 
concentration of rPjEDcys hybrid (f). Numbers inside the graphs indicate the percentage of CD4+ CD25++ 
cells. 
 
In summary, these data demonstrated that using the two-step magnetic purification we obtained an 
enrichment of CD4+CD25++CD127- Tregs from human PBMC.  
The analyses on enriched CD4+CD25++CD127- have shown that the stimulation with a mixture of 
rPar j 1 and rPar j 2 allergens and rPjEDcys induced an increase in the percentage of activated 
CD4+CD25++ of 1.9% and 1.7% respectively.  
The most significant results emerged from the analysis of the expression of CD25 on 
CD4+CD25++CD127- fraction.  
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Figure 42 shows the histograms related to the intensity of CD25 expression in 
CD4+CD25++CD127- cell fraction after 8 days in culture. The number of events per intensity of 
fluorescence in the mixture of wild type allergen-treated (solid blue histogram) and rPjEDcys-












The histograms have shown that at day 8, the in vitro stimulation with wild type allergens and 
hypoallergenic hybrid rPjEDcys induced an increase of cells expressing high CD25 on their cell 
surface.  
As previously said CD25 is expressed by Tregs and also by activated effector T cells, but the 
density of CD25 expression allows us to discriminate between these two T cell populations. 
Therefore, a more interesting data emerged by the analysis on the number of events that showed 
high-density expression of CD25. In particular, our analysis showed that only after the in vitro 
stimulation with hypoallergenic hybrid, the Mean Fluorescence Intensity (MFI) of CD25 
expression in CD4+ cells increased compared to an unstimulated culture. The MFI measure the 
shift in fluorescence intensity of a population of cells.  The described experiments have 
demonstrated that PBMC stimulation with hypoallergenic hybrid for 8 days induced a significant 
increase of CD4+ CD25++ CD127- cell population. 
 
 Mean of Fluorescence 
(MFI) 
Unstimulated 178 
rPar j 1 + rPar j 2 156 
rPjEDcys 198 
Fig. 42. Histograms of the CD25 expression intensity on CD4+CD25++ cells. Histograms in 3D (A) and Mean 
of fluorenscence of CD25 expression (B) in CD4+CD25++CD127- cell fraction after 8 days in culture. The 
intensity of fluorescence in mixture of wild type allergens-treated (blue line) and rPjEDcys-teatred (violet line) 

















7. Molecular characterization of allergen-specific CD4+ CD25++ CD127- T Regulatory Cell  
 
PBMC isolated from each patient were contextually cultured in presence of 10 µg/ml of antigens 
for 8 days in order to isolate and characterize the CD4+CD25++CD127- Tregs using a two-step 
magnetic purification MACS procedure, as previous described. 
I performed reverse transcription and quantitative PCR experiments on RNA extracted from the 
CD4+CD25++CD127- cell fractions, obtained after the magnetic separation, in order to characterize 
which Tregs subset was activated after the in vitro stimulation with the mixture or the hybrid. 
The cDNA obtained from 6 patients were used as a template for Real Time PCR reactions.  
We looked at the expression levels of four genes encoding for proteins essential for the 
development and function of Tregs. Using RT-qPCR we measured the FoxP3, IL-10, GARP and 
TGF-β mRNA levels in the enriched CD4+CD25++CD127- cells after an in vitro stimulation. The 
transcription factor FoxP3 was described as the “master regulator” Treg [31, 39]. But, not all Tregs 
express FoxP3, there are other types of Treg cells that can be induced from naïve T cells in the 
periphery which are FoxP3-. These different subsets have been identified and show different 
phenotype and suppressive activity [125]. The mRNA levels of TGF-β cytokine, 
immunosuppressive cytokines involved in regulatory pathway of Tregs, were also analyzed. 
Recently the expression of a gene encoding for a transmembrane proteins called GARP was 
identified on human Tregs activated only after TCR stimulation [126-129]. FoxP3, IL-10, TGF-β 
and GARP expression were standardized using the human housekeeping 18S rRNA. The 
experiment was repeated in triplicate with similar results, as shown in figure 43. Panels A-F of 



































































Analysis of FoxP3 gene expression on enriched CD4+CD25++CD127- cell fractions showed that in 
four out of six analyzed patients (patients 1-3 and 5) the PBMC stimulation with the mixture of 
wild type allergens or rPjEDcys induced an increase of FoxP3 mRNA levels. In three out of these 
four patients (patients 1, 3 and 5) RTq-PCR revealed significantly higher expression levels of the 
relevant FoxP3 mRNA in isolated CD4+CD25++ CD127- cells in response to rPjEDcys as 
compared to the mixture of Parietaria allergens.   
In two out of six analyzed patients (patients 4 and 6) RTq-PCR did not revealed higher expression 
levels of the FoxP3 mRNA in isolated CD4+CD25++ CD127- cells in response to both antigens. 
Our results about the analysis of IL-10 expression on enriched CD4+ CD25++ CD127- cell fraction 
showed that in five out of six analyzed patients (patients 1-5) IL-10 mRNA levels increase in the 
sample stimulated with both antigens.  
Fig. 43. Histograms of percentage of gene expression. Real-time PCR analysis of FoxP3 and IL-10 
mRNA expression in enriched CD4+ CD25++ CD127- cell fraction treated with the mixture of wild type 
allergens or with the rPjEDcys compared to the unstimulated sample. 
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Moreover, in four out of six analyzed patients (patients 1, 2, 4 and 5) quantitative PCR revealed 
that the rPjEDcys induced a significantly higher expression levels of the relevant IL-10 mRNA in 
CD4+CD25++ CD127- cells than the mixture of Parietaria allergens.  
Patient 6 was the only one where the PBMC stimulation with the mixture of allergens or rPjEDcys 
did not induce an increase of mRNA levels for each genes.  
In summary, our analyses on FoxP3 and IL-10 gene expression showed a similar increasing trend 
in response to the mixture and the hypoallergenic hybrid. On the contrary, our analyses on TGF-β 
mRNA levels expression did not show an increase in response to antigen-specific stimulation (data 
not shown).Our analyses on GARP mRNA levels showed high variability within and between 
patients, therefore our analyses confirmed the data published in literature, which suggest the 
almost undetectable GARP mRNA level in CD4+ T cells and a post-transcriptional regulation of 
GARP expression [38, 129].  On the contrary, our analyses on TGF-β mRNA levels expression did 
not show an increase in response to antigen-specific stimulation (data not shown). 
 
8. Analysis of GARP and LAP expression on CD4+CD25++ cells in response to Parietaria major 
allergens and rPjEDcys 
 
In recent years, GARP expression was found to be highly expressed on activated T regulatory 
cells. Recent studies suggested the possibility of using GARP as a marker to detect activated T reg 
cells with suppressor functions. However, Unutmaz et al. (the first one to identify GARP mRNA 
into Treg cells) showed that GARP was expressed only after TCR stimulation of Treg [126]. 
In addition, GARP mRNA expression was definided undetectable in freshly isolated CD4+ T cells; 
on the contrary the GARP protein accumulates on Treg cell surface post activation [36-37, 128-
129].  
Thanks to the discovery of GARP function, a new interested was given to TGF-β on Treg cell 
biology. GARP function is associated with latent transforming growth factor-β (proTGF-β) on 
Treg cell surface and regulates Treg activation [130].  
GARP was in fact identified as a receptor for latent TGF-β providing an explanation for the 
detection of membrane-bound TGF-β on Treg cells, as reported by several groups [130-131] 
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To study the expression of GARP and LAP on CD4+CD25++ cell surface induced by in vitro 
stimulation with the mixture or rPjEDcys, we stimulated PBMC from four allergic patients for a 
time course of 6 days (as shown in Materials and Methods).  
The negative control sample was treated, exactly the same as the antigenstimulated sample, but 
without addition of antigens. Cells were recovered at 2h, 4h, 6h, 18h, 24h and then every 24 hours 
until day 6 and analyzed for the expression of CD4, CD25, GARP or LAP by multiparametric 
flow cytometry.  
Therefore, analyzed cells were selected by a live lymphocyte gate based on the combination of 
FSC and SSC and were selected also by a gate on the expression of CD4 and CD25 (as shown 
before). 
Figure 44 shows a flow cytometric analysis on CD4+ CD25++ GARP+ cells from a representative 
























Unstimulated rPar j 1+ rPar j 2 rPjEDcys 
6 
Fig. 44. Representative 
flow cytometric Dot Plot 
analysis of 
CD4+CD25++GARP+ cells.  
Panels show cytometric 
analyses of CD4+ CD25++ 
GARP+ cells in a 
representative patient 
(patient 1). Numbers inside 
the graphs indicate the 
percentage of CD4+ CD25++ 






The results obtained from the analyses of GARP expression on CD4+ CD25++ cells showed that 
PBMC stimulation with the wild type allergens or rPjEDcys induce an increase in the percentage 
of CD4+ CD25++ GARP+ cells. Furthermore, we observed that CD4+ CD25++ population started to 
express the GARP protein on cell surface 2h after the in vitro stimulation and the expression of 
GARP was higher in response to rPjEDcys than to the mixture, (8.1% and 1.2% respectively).  
After 6h, an increase in percentage of CD4+ CD25++GARP+ cells was exclusively observed in the 
PBMC stimulated with the mixture. Our preliminary data show that the in vitro stimulation of 
human PBMC from allergic patients with both the w.t. antigens and the derivative induced an 
increase of CD4+ CD25++ GARP+ cells after 2 days. Moreover, GARP expression increases until 
day 3 only in response to rPjEDcys. 
In this experimental set up we also analyzed the expression of LAP on CD4+CD25++ cells after in 
vitro stimulation with the mixture or rPjEDcys.  For this reason, cells were selected by a 
lymphocyte gate (R1) based on the combination of FSC and SSC and were also selected by a R2 
gate based on the expression of CD4 and CD25 (as shown before). 









































Fig. 45. Representative 
flow cytometric Dot 
Plot analysis of 
CD4+CD25++LAP+ cells.  
Panels show cytometric 
analyses of CD4+ 
CD25++ LAP+ cells in a 
representative patient 
(patient 1). Numbers 
inside the graphs 
indicate the percentage 







The results obtained from the analyses of LAP expression on CD4+ CD25++ showed that the 
PBMC stimulation with the wild type allergens or rPjEDcys increase the percentage of CD4+ 
CD25++ LAP+ cells. We observed that the LAP expression on CD4+ CD25++ cells started to 
increase 4h after the in vitro stimulation with the mixture or rPjEDcys (8.5% and 8.6% 
respectively).  
In the sample stimulated with the mixture of Parietaria allergens, LAP protein is expressed on 
CD4+CD25++ cells until day 2. The percentage of CD4+ CD25++ LAP+ cells increased at 4h after 
PBMC stimulation with the mixture and reached the peak after 6h. Afterwards, the percentage of 
CD4+ CD25++ LAP+ strongly increased 24h after PBMC stimulation.  
Our analysis showed that the percentage of CD4+ CD25++ LAP+ cells increased within 2h after in 
vitro stimulation with hypoallergenic hybrid, compared to an unstimulated culture. The percentage 
of CD4+ CD25++ LAP+ cells reached the peak at 6h and then progressively decreased until 24h. 



















Fig. 46. Histograms of percentage of CD4+CD25++GARP+ and CD4+CD25++LAP+ cells. Graphics show he 
percentage of activated CD4+CD25++GARP+ cells (A) and CD4+CD25++LAP+  (B) in a representative patient 
(patient 1), after in vitro stimulation with the mixture of wild type allergens and rPjEDcys subtracted of the 
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Starting from this preliminary experiment and data in licterature, we decided to perform another 
set of experiments in order to study the CD4, CD25, GARP and LAP expression [36, 129]. In the 
successive experiments the PBMC were stimulated for a time course of 3 days. In fact, from the 
first experiment we observed that cell surface expression of either GARP or LAP was not detected 
after 3 days in culture except for a low increase in percentage of CD4+CD25++LAP+ on day 5. 
Studies in literature showed that the level of GARP mRNA increased during the first 6 hrs after 
TCR stimulation. Moreover, the levels of GARP and LAP proteins were analyzed until 24 hrs after 
cell stimulation [129]. The data reported in panels A-D of figure 47 shows the histograms 






















Our analyses on four Parietaria allergic patients showed a rapid GARP expression on 
CD4+CD25++ cells in response to both antigens. GARP expression increased 2-6 hrs post PBMC 
% CD4+CD25++GARP+ cells 
 
Fig. 47. Histograms of percentage of CD4+CD25++GARP+. Graphics show the percentage of activated 
CD4+CD25++GARP+ cells in all four analyzed patients (A-D) after in vitro stimulation with the mixture of wild 
























stimulation with rPjEDcys in all four analyzed patients. On the contrary, PBMC stimulation with 
the mixture of rPar j 1 and rPar j 2 showed that GARP expression started later than that one in 
rPjEDcys stimulated sample (4-6 hrs post-stimulation). In two out of four analyzed patients 
(patients 1 and 2) GARP showed a late expression at day 2 and day 3 post-stimulation in response 
to both antigens. However, in all patients GARP expression in response to the hypoallergenic 
hybrid and the mixture appears to have a early kinetic of expression. 
The histogram reported in panels A-D of figure 48 show the results concerning to the LAP 






















Our analyses on four Parietaria allergic patients showed a rapid LAP expression on CD4+CD25++  
cell surface. LAP expression increased from 4 hrs to 24 hrs post PBMC stimulation with rPjEDcys 
in all four analyzed patients, and it reached its peak at 6hrs. 
Fig. 48. Histograms of percentage of CD4+CD25++LAP+ cells. Graphics show the percentage of activated 
CD4+CD25++ LAP+ in four analyzed patients (A-D) after in vitro stimulation with the mixture of wild type 
allergens and rPjEDcys, subtracted of the background in the unstimulated culture. 
























Taking together our analyses on LAP and GARP expression on four Parietaria allergic patients on 
CD4+CD25++ cell surface it appears that the two antigens have a different temporal regulation with 
an early GARP expression followed by the LAP expression.  
The kinetic of LAP expression in response to the mixture of wild type allergens is less definite. 
Moreover, these results show that PBMC stimulation with rPjEDcys induces an higher percentage 
of CD4+CD25++GARP+ and CD4+CD25++LAP+ cells than the mixture of wild type allergens. 
 
9. Study of GARP and LAP co-expression on CD4+CD25++ cells after PBMC stimulation with 
the mixture of wild type allergens and the hypoallergenic derivate 
  
As, previously shown, PBMC stimulation with the mixture of wild type allergens and the 
hypoallergenic hybrid induced the modulation of GARP and LAP expression on CD4+CD25++ 
cells. Starting from our preliminary data, by means of a multiparametric flow cytometry analysis 
we wished to study the kinetics of co-expression of GARP and LAP, simultaneously to the 
expression of CD4 and CD25. 
To do this, we purified human PBMC from heparinized peripheral blood of three Parietaria 
judaica allergic patients. PBMC were stimulated until 6 hrs with Parietaria major allergens and 
rPjEDcys. Negative control sample was treated without addition of antigens. 
Cells were recovered at 2 hrs and 6 hrs, based on results of previous experiments mentioned 
above, and analyzed for the co-expression of CD4, CD25, GARP and LAP. 
Therefore, analyzed cells were selected by a lymphocyte gate (R1) based on the combination of 
FSC and SSC and were selected also by a R2 gate based on CD4+CD25++ cell population 
(CD4/CD25). 
Figure 49 shows a flow cytometric analysis on CD4+CD25++GARP+LAP+ cells from the 


















The results obtained from our analyses show that only the PBMC stimulation for 2 hrs with 
PjEDcys induced a 2.7% increase in the percentage of CD4+CD25++GARP+LAP+ cells compared 
to unstimulated sample. PBMC stimulation for 6 hrs with both the wild type allergens and 
rPjEDcys induced an increase of GARP and LAP co-expression of 1.7% and 1.8 % respectively.  
The data reported in panels A-C of figure 50 show the results concerning the GARP and LAP co-




Fig. 49. Representative flow cytometric Dot Plot analysis of CD4+ CD25++ GARP+ LAP+ cells.  Panels 
show cytometric analyses of CD4+CD25++GARP+LAP+ cells in a representative patient (patient 1) after 2 
hrs (a.- c.) and 6 hrs (d.- f.) PBMC in vitro stimulation with the mixture of wild type allergens and 
rPjEDcys. Numbers inside the graphs indicate the percentage of CD4+CD25++GARP+LAP+ cells compared 
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Our analyses showed that in two out of three analyzed patients (patients 1 and 2), PBMC 
stimulation with the mixture induced an increase in percentage of CD4+CD25++ cells co-
expressing GARP and LAP molecule compared to the unstimulated sample. In all three analyzed 
patients, PBMC stimulation with rPjEDcys induced an increase in percentage of 
CD4+CD25++GARP+LAP+ compared to the unstimulated sample.  
Taking together our analyses on LAP and GARP co-expression on CD4+CD25++ cells in all three 
Parietaria allergic patients showed that PBMC stimulation with hybrid increases always the 
GARP and LAP co-expression at 2hrs or 6hrs depending on the individual response. On the 
contrary, PBMC stimulation with the mixture induced the co-expression of GARP and LAP on 
CD4+CD25++ cells in two out of three patients (patients 1 and 2). 
 
10. Analysis of CD39 expression on CD4+ cells in response to Parietaria major allergens and 
rPjEDcys 
 
In the previous experiments we studied the selection of Tregs after PBMC stimulation with the 
mixture of wild type allergens and rPjEDcys. At the beginning, we evaluated the modulation of 
CD25 and CD127 expression on CD4+ cells from allergic patients by means of 
% CD4+CD25++GARP+LAP+ cells 
 
 
Fig. 50. Histograms of percentage of 
CD4+CD25++GARP+LAP+ cells. Graphics 
show the percentage of 
CD4+CD25++GARP+LAP+cells in all three 
analyzed patients (A-C) after in vitro 
stimulation with the mixture of wild type 
allergens and rPjEDcys, subtracted of the 





immunophenotyping. A major limitation in the study of regulatory T cells is a lack of unique cell 
surface markers. Recent paper suggest to study the human Treg cells based on the expression of 
functional markers [127-129, 132]. We already studied the kinetic expression of two functional 
markers, as GARP and LAP on CD4+CD25++ cells. Since Treg cells employ multiple 
immunoregulatory mechanisms, I decided to study also the adenosine pathway. 
In fact, a growing body of evidence supports an important role for the Treg activities mediated by 
CD39/CD73 adenosine pathway in regulating immune response.  
CD39 is a cell surface ecto-enzyme that regulate levels of ATP and adenosine in extracellular 
microenvioroment [132].  
This ecto-enzyme mediates principally anti-inflammatory effects by dephosphorylating ATP into 
ADP and then into AMP. AMP produced by CD39 is then converted into adenosine by another 
ecto-enzyme, as CD73 [133]. CD39 is uniformly and highly expressed by CD4+CD25++ T cells 
with suppression activities and it may participate in the immunoregulatory role of Treg cells. 
CD39 has been considered critical in the generation of immunosuppressive microenvironments 
through adenosine production as shown in several diseases, such as autoimmunity, cancer, allergy 
and allograft rejection. In the immune system, adenosine inhibits functions of innate and adaptive 
immune cells and it is considered to be a crucial anti-inflammatory factor [133-136].   
In order to study the modulation of CD39 on CD4+ cell induced by in vitro stimulation with the 
mixture or rPjEDcys, PBMC were stimulated for a time course of 8 days (as shown in Materials 
and Methods). As usual, the negative control sample was treated without addition of antigens. 
Cells were recovered at 2h, 4h, 6h, 24h and then every 24 hours until day 8 and analyzed for the 
expression of CD4 and CD39 by flow cytometry.  
Therefore, analyzed cells were selected by a live lymphocyte gate based on the combination of 
FSC and SSC and were selected also by a gate based on the expression of CD4 (SSC/CD4+) (data 
no shown). 
Figure 51 shows a flow cytometric analysis on CD4+ CD39+ cells from a representative patient 






Fig. 51. Representative flow 
cytometric Dot Plot analysis 
of CD4+ CD39+ cells. Panels 
show cytometric analyses of 
CD4+CD39+ cells in a 
representative patient (patient 
1) after in vitro stimulation 
with the mixture of wild type 
allergens and rPjEDcys. 
Numbers inside the graphs 
indicate the percentage of 
CD4+CD39+ cells compared to 
the unstimulated culture.  
Unstimulated rPar j 1 + rPar j 2 rPjEDcys 
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From these analyses we showed that CD4+CD39+ population started to increase from day 4 and 
reached its peak at day 8, only after PBMC stimulation with rPjEDcys. These analyses highlight 
that PBMC stimulation with the mixture of wild type allergens did not induce an increase in 
percentage of CD4+CD39+ compared to unstimulated sample. 
This pattern of activation was observed in two analyzed patients with some differences during the 
time course of stimulation (Fig. 52). The pattern of activation reached the peak at day 8, in both 











Fig. 52. Histograms of percentage of CD4+CD39+cells. Graphics show the percentage of 
CD4+CD39+cells in two analyzed patients (A-B) after in vitro stimulation with the mixture of wild 
type allergens and rPjEDcys, subtracted of the background in the unstimulated culture. 
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11. Evaluation of putative cross-talk between two suppressive pathways of human Treg cells 
 
The expression of CD39 and CD73 on Treg cells and the capacity to convert ATP into adenosine 
has been suggested as one of Treg suppressive actions. Recent data indicated a possible cross-talk 
between regulatory pathways, as the connection between the TGF-β and the adenosine pathways 
[137-138]. Mouse studies have shown that the addition of TGF-β to cultures of activated splenic T 
cells demonstrated a clear effect on CD39 and CD73 expression.  In fact, the up-regulation of both 
antigens was enhanced in the presence of TGF-β; possibly leading to the amplification of the 
adenosine pathway in a microenvironments enriched with this cytokine [137]. In 2015, Mann et al 
confirmed the connection between the two suppressive pathways in human; a significant 
proportion of CD4+ T cells co-express CD73 with GARP and LAP [138].  
Therefore, I wanted to investigate if the PBMC stimulation with the mixture of Parietaria judaica 
major allergens or the hypoallergenic derivate induced the cross-talk between the two regulatory 
pathways. In particular, we were interested in studying the co-expression of CD39, the first 
enzyme involved in adenosine pathway, with GARP and LAP molecules on the surface of CD4+ T 
cells. To do this, PBMC from two Parietaria judaica allergic patients were stimulated for a time 
course of 8 days (as shown in Materials and Methods). The negative control sample was treated 
without addition of antigens. Cells were recovered at 2 hrs, 4 hrs, 6 hrs, 24 hrs and then every 24 
hours until day 8 and analyzed for the expression of CD4, CD39, GARP or LAP by flow 
cytometry.  
Therefore, analyzed cells were selected by a live lymphocyte gate based on the combination of 
FSC and SSC and were selected also by a gate based on the expression of CD4 (SSC/CD4+) and a 
gate based on the expression of GARP or LAP (SSC/GARP or SSC/LAP+). 
Figure 53 shows a flow cytometric analysis on CD4+ CD39+ GARP + cells from a representative 
patient (patient 1) during the PBMC early stimulation, from 2 hrs until 3 days. This is the same 
time course followed during the GARP and LAP expression analysis on CD4+CD25++ cells, as 


















Fig. 53. Representative 
flow cytometric Dot Plot 
analysis of 
CD4+CD39+GARP+ cells 
(from 2 hrs until day 3). 
Panels show cytometric 
analyses of CD4+CD39+ 
GARP+ cells in a 
representative patient 
(patient 1) after in vitro 
stimulation with the 
mixture of w.t. allergens 
and rPjEDcys. Numbers 
inside the graphs indicate 
the percentage of 
CD4+CD39+GARP+ cells 
compared to an 
unstimulated culture. 








The analyses on early PBMC stimulation for this representative patient have shown that the 
PBMC stimulation with the mixture of w.t. allergens and the rPjEDcys increase the percentage of 
cells co-expressing CD39 and GARP. We observed a low increse in percentage of cells co-
expressing CD39 and GARP molecule after 2hrs of stimulation in the sample stimulated with the 
mixture and 1 and 3 days after PBMC stimulation with both mixture and rPjEDcys.  
However, data in literature define CD39 as activation marker expressed only by activated Treg 
cells [139]. Moreover, our data showed that CD4+CD39+ population started to increase from day 4 
and reached its peak at day 8 after PBMC in vitro stimulation with rPjEDcys.  
Therefore, we decided to analyze the co-expression of GARP and CD39 also for a longer time-
course of stimulation, in fact our analyses were continued until day 8.  
Panels of figure 54 show the cytofluorimetric analyses of CD4+CD39+ GARP+ cells after in vitro 
stimulation with the mixture of wild type allergens or the hypoallergenic rPjEDcys and in an 












Fig. 54. Representative flow cytometric Dot Plot analysis of CD4+ CD39+ GARP+ cells (from day 4 through 
8). Panels show cytometric analyses of CD4+ CD39+ GARP+ cells in a representative patient (patient1) after in 
vitro stimulation with the mixture of w.t. allergens and rPjEDcys. Numbers inside the graphs indicate the 
percentage of CD4+CD39+ GARP+ cells compared to an unstimulated culture. 
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Long-term PBMC stimulation with the mixture and rPjEDcys significantly increased the 
percentage of CD4+ cells co-expressing both CD39 and GARP molecules compared to an 
unstimulated sample. From these analyses we observed that CD4+CD39+GARP+ population began 
to increase from day 6 through day 8. These analyses highlight that the co-expression of CD39 and 
GARP is more sugnificative in the sample stimulated with rPjEDcys compared to the wild type 
allergen stimulation. 
The histograms reported in panels A-B of figure 55 show the data concerning the percentage of 
CD4+ cells co-expressing GARP and CD39 molecule in two analyzed patients. 
 
% CD4+CD39+GARP+ cells 
Fig. 55. Histograms of percentage of CD4+CD39+ GARP+ cells. Graphics show the percentage of activated 
CD4+CD39+ GARP+ cells in two analyzed patients (A-B) after in vitro stimulation with the mixture of wild 





Our analyses show that in one out of two patient (patient 1) PBMC stimulation with the mixture of 
w.t. allergens induces the co-expression of GARP and CD39 on CD4+ cells compared to 
unstimulated sample. The percentage of cells co-expressing both molecules is induced at 4hrs and 
at 24 and 48hrs after stimulation and it increases again at day 6. Analysis on patient 1 showed that 
PBMC stimulation with the hypoallergenic derivate, induces a significant increase in percentage of 
CD4+CD39+ GARP+ cells which starts at day 1 until day 3 after in vitro stimulation. Moreover, this 
increase reach a more significative value from day 6 to day 8. Neverthless, the co-expression of 
both molecules is higher and more significant in the sample stimulated with rPjEDcys compared to 
the mixture. 
The analyses on patient 2 have showed that PBMC stimulation, at 2hrs and then between day 1 
and day 4, with both the mixture and the rPjEDcys induced a high increase in percentage of 
CD4+CD39+ GARP+ compared to unstimulated sample. On the contrary, at day 8, only PBMC 
stimulation with rPjEDcys induced an increase of GARP and CD39 co-expression on CD4+ cells. 
Also in patient 2 PBMC stimulation with rPjEDcys induced an higher percentage of CD4+CD39+ 
GARP+ cells than those induced by the mixture. 
 
Furthermore, we also analyzed the co-expression of CD39 and LAP molecules on CD4+ cells. 
Figure 56 shows a flow cytometric analysis on CD4+ CD39+ LAP + cells from the same 































Unstimulated rPar j 1 + rPar j 2 rPjEDcys 
Fig. 56. Representative 
flow cytometric Dot 
Plot analysis of 
CD4+CD39+LAP+ cells 
(from 2 hrs until day 
3). Panels show 
cytometric analyses of 
CD4+ CD39+ LAP+ cells 
in a representative 
patient (patient 1) after 
in vitro stimulation with 
the mixture of w.t. 
allergens and rPjEDcys. 
Numbers inside the 
graphs indicate the 
percentage of 
CD4+CD39+ LAP+ cells 













Cytofluorimetric analyses of CD39 and LAP co-espression on CD4+ cells have shown that the co-
expression of both these functional markers is induced at significative levels in an early PBMC 
stimulation with the mixture or rPjEDcys. Moreover, it is higher in the sample stimulated with the 
hypoallergenic hybrid. PBMC stimulation with the rPjEDcys increased the percentage of 
CD4+CD39+LAP+ cells 1 days after stimulation compared to an unstimulated sample (1.1% and 
4.9% respectively). At day 3, only PBMC stimulation with rPjEDcys induced an increase of LAP 
and CD39 co-expression on CD4+ cells.  
The LAP and CD39 co-expression on CD4+ cells was also investigated in a longer PBMC 
stimulation time with both antigens. Figure 57 shows a flow cytometric analysis on CD4+ CD39+ 













Fig. 57. Representative flow cytometric Dot Plot analysis of CD4+ CD39+ LAP+ cells (from day 4 through 8). 
Panels show cytometric analyses of CD4+ CD39+ LAP+ cells in a representative patient (patient 1) after in vitro 
stimulation with the mixture of w.t. allergens and rPjEDcys. Numbers inside the graphs indicate the percentage of 













Our analyses for this representative patient (patient 1) have shown that the PBMC stimulation with 
the mixture of w.t. allergens and the rPjEDcys increased the percentage of cells co-expressing 
CD39 and LAP.  These analyses highlight that PBMC stimulation with the mixture of w.t. 
allergens induced an increase in percentage of CD4+CD39+LAP+ cells in comparison to 
unstimulated sample. This increase was observed 4 days after PBMC stimulation until day 5. On 
the other hand, rPjEDcys was able to induce a more significative increase in the percentage of 
CD4+ cells co-expressing CD39 and LAP from day 4 through day 8. 
The histograms reported in panels A-B of figure 58 shows the data concerning to the percentage of 

























Our analysis of LAP and CD39 co-expression on CD4+ cells showed that in one out of two 
analyzed patients (patient 1) the PBMC stimulation for 2hrs with both mixture and the 
hypoallergen induced an increase in percencentage of CD4+CD39+ LAP+. At day 5, PBMC 
Fig. 58. Histograms of percentage of CD4+CD39+ LAP+ cells. Graphics show the percentage of activated 
CD4+CD39+ LAP+ cells in two analyzed patients (A-B) after in vitro stimulation with the mixture of wild 
type allergens and rPjEDcys, subtracted of the background in the unstimulated culture. 














stimulation with the mixture indue an increase in the percentage of these cells. However, from day 
3 until day 8, only PBMC stimulation with rPjEDcys induced a significative increase of LAP and 
CD39 co-expression on CD4+ cells. Analyses on patient 2 have shown a early increase of LAP 
CD39 co-expression, between 2 and 6 hrs, which was higher in response to the rPjEDcys. The data 
on two patients demonstrated that PBMC stimulation with both the mixture and the hypoallergenic 
derivate induced an increase of CD39 and LAP co-expression on CD4+ cells compared to 
unstimulated sample. However, the co-expression of both molecules is higher and more significant 
in the sample stimulated with rPjEDcys compared to the mixture. 
 
12. Analysis of PD1 expression on CD4+ CD25++ cells in response to Parietaria major allergens 
and rPjEDcys 
 
It has been reported that T reg play an important role in allergic diseases. Modulation of functions 
of Tregs may provide a novel strategy to prevent and treat allergic diseases. In recent years, it is 
recognized that Tregs cells play different inhibitory pathways to prevent hypersensitive immune 
responses and the underlying sensitization to allergens. Recent studies are just beginning to 
elucidate the role of PD1 pathway in allergy and asthma. PD1 is an immunoinhibitory receptor that 
belongs to the CD28 family with a is a critical role in the regulation of T cell activation. It has also 
been shown that PD-1 is up-regulated on T cells upon activation, and its ligands have distinct 
expression patterns, PD-L1 is expressed much more abundantly than PD-L2. In order to study the 
modulation of PD1 on CD4+ cell induced by in vitro stimulation with the mixture or rPjEDcys, 
PBMC from two allergic patients were stimulated for a time course of 8 days. Cells were 
recovered at 2h, 4h, 6h, 24h and then every 24 hours until day 8 and analyzed for the expression of 
CD4 and CD39 by flow cytometry. Therefore, analyzed cells were selected by a live lymphocyte 
gate based on the combination of FSC and SSC and were selected also by a gate based on the 
expression of CD4 and CD25 (CD4+/CD25+) (data no shown). 



















































Fig." 59. Representative 
flow cytometric Dot 
Plot analysis of 
CD4+CD25++PD1+ cells 
(from 2hrs until day 3). 
Panels show cytometric 
analyses of 
CD4+CD25++PD1+ cells 
in a representative 
patient (patient 1) after 
in vitro stimulation with 
the mixture of w.t. 
allergens and rPjEDcys. 
Numbers inside the 
graphs indicate the 
percentage of 
CD4+CD25++PD1+  cells 
















































Unstimulated rPar j 1 + rPar j 2 rPjEDcys 
Fig."60. Representative flow cytometric Dot Plot analysis of CD4+CD25++PD1+ cells (from day 4 
through 8). Panels show cytometric analyses of CD4+CD25++PD1+ cells in a representative patient 
(patient 1) after in vitro stimulation with the mixture of w.t. allergens and rPjEDcys. Numbers inside the 




We observed an increase in the percentage of PD-1-expressing cells in CD4+CD25++cells after 
PBMC stimulation with the mixture and rPjEDcys. This increase was observed both in short  than 
long time course of stimulation and it is generally higher after the PBMC stimulation with the 
hybrid rPjEDcys than wild type allergens. 
The histograms reported in panels A-B of figure 61 shows the data concerning to the percentage of 




















The increase in percenatge of CD4+CD25++PD1+ cells after PBMC stimulation with both antigens 
has been observed in two analyzed patients; this was higher in response to rPjEDcys. 
Starting from the evidence that the number of CD4+CD25++PD1+ cells induced after PBMC 
stimulation with the mixture and rPjEDcys is very low, only 0.1 to 0.5% of the total cells, we 
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Fig. 61. Histograms of percentage of CD4+CD25++PD1+ cells. Graphics show the percentage of 
activated CD4+CD25++PD1+ cells in two analyzed patients (A-B) after in vitro stimulation with the 




Figure 61 shows the histograms related to the intensity of PD1 expression in CD4+ CD25++cells in 



















In these experiments we show an increase in number of CD4+ CD25++ PD1+ cells after PBMC 
stimulation with rPjEDcys than w.t. allergens.  Moreover, the MFI of PD1 expression in these 
cells after the in vitro stimulation with the rPjEDcys is significantly higher. 
We used the coefficient of variation (CV), also known as relative standard deviation to determine 
the statisticial significance of  PD1 expression on CD4+ CD25++(CV< 5).  
 
Discussion  
Allergy is an immunological disorder affecting about 30% of the population living in the 
industrialized countries. The etio-pathogenesis of allergy is complex and influenced by many and 
different factors, including the genetic variation among individuals, the allergen dose and time of 
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Fig. 62. Histograms of value of MFI of PD1 expression in CD4+CD25++ cells. Graphics show the 
value of MFI of PD1 expression in CD4+CD25++ cells in two analyzed patients (A-B) after in vitro 





alleviate the symptoms arising from the allergens; however, allergen immunotherapy is the only 
valid treatment able to modify the underlying pathological mechanisms of immune response and to 
have a long-lasting effect. SIT is a form of immunotherapy for allergic disorders in which the 
patient is vaccinated with gradually increasing doses of an allergen with the aim of inducing 
immunological tolerance. The molecular mechanisms involved in successful immunotherapy are 
not fully understood and several factors seem to influence the immune response such as the 
concentration of the allergen, the type of antigen-presenting cell and the type of adjuvant used for 
the formulation of vaccine. Several clinical evidences suggest the advantages of using recombinant 
allergens for immunotherapy [99]. Recombinant allergens can be produced as molecules with the 
same properties to their native counterparts or natural allergens (i.e., recombinant wild-type 
allergens); or as modified variants with advantageous properties such as reduced allergenic activity 
and increased immunogenicity; for example, as hybrid molecules resembling the epitopes of 
several different allergens to include the relevant epitopes of complex allergen sources. Moreover, 
recombinant allergens offer the possibility to use well-defined molecules with consistent 
pharmaceutical quality defined in mass units.  
Parietaria judaica is the main allergenic source in the Mediterranean area. It has a long period of 
pollination, starting in the spring and lasting up to the autumn. Par j 1 and Par j 2 were classified 
as the two major allergens of Parietaria pollen and display some cross-reactive and independent 
IgE epitopes. Therefore the generation of a recombinant single protein comprising the major 
allergens of Parietaria pollen and containing their main B-cell and T-cell epitopes in one 
pharmaceutical product may reduce the production costs, providing a therapy that has the aim of 
modifying allergen-specific immune response towards the two major allergens of Parietaria 
pollen. This recombinant hybrid was previously produced and its low allergenic activity was 
demonstrated by Bonura et al. [118]. 
In order to test other properties of this protein, the immunogenicity of the hypoallergenic hybrid 
was studied in vitro, looking at the main immunological mechanisms involved in allergic 
inflammation and immune tolerance after specific immunotherapy (SIT). 
We studied the PBMC proliferative response after the in vitro stimulation with a mixture 
containing the two recombinant (wild-type) Parietaria allergens (rPar j 1 and rPar j 2) and the 
hypoallergenic hybrid, rPjEDcys. Our data showed CD4+ cells are clearly the major cell 
population proliferating in response to the mixture of wild-type allergens and to the rPjEDcys. The 
percentage of CD4+ proliferating cells in response to rPjEDcys is higher when used at lower than 
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high concentration. Furthermore, the hypoallergenic hybrid scored a percentage of CD4+ 
proliferating cells higher than the wild type allergens when used at the lower concentration. 
A few reports demonstrated that allergens are inducers of both the innate and acquired immune 
systems.  We were able to demonstrate that components of innate immune system (CD56+ cells) 
are activated both by the mixture of Parietaria allergens and by the rPjEDcys hybrid, leading to 
the proliferation of these cells in allergic patients.  
Starting from these results, we decided to look at the cytokines produced by T CD4+ cells upon an 
antigen-specific stimulation. In fact, once activated, CD4+ T cells play a main role in the 
regulation of immune response through the secretion of specific cytokines.  
Allergic individuals generally show a Th2 biased immune response and several studies have 
shown that immune response to allergens in healthy individuals is characterized by the Treg (IL-10 
secreting) and Th0/Th1 immune polarization [80, 140-141]. Healthy and allergic individuals 
display the same allergen-specific T cell subsets (Th1, Th2 and Tregs) but with different 
proportions. The main difference between healthy and allergic individuals is the nature of the 
immune response, which is characterized by a different balance between allergen-specific T 
regulatory cells and allergen-specific Th2 cells [141].  
In these experimental settings, we were able to demonstrate that PBMC from Parietaria allergic 
patients stimulated with the wild type allergen mixture was predominantly of the Th2 type (IL-5 
and IL-13). IL-5 secretion assays showed that PBMC from seven out of ten patients stimulated 
with rPjEDcys induced a lower percentage of IL-5 secreting T CD4+ cells compared to wild type 
allergen stimulation. These results are very interesting because IL-5 has been shown to play an 
important role in allergic diseases, including allergic rhinitis and asthma. Actually many studies 
identify IL-5 as a primary therapeutic target for the improvement of the treatment of allergy.  
Moreover, in eight out of the ten patients analyzed, rPjEDcys induces a lower percentage of IL-13 
secreting CD4+ cells, compared to that induced by wild type allergens. 
This is another encouraging result because IL-13 has been proposed to be a cytokine mainly 
nvolved in the chronicity of allergic inflammation, and because in vivo studies in mouse model of 
allergic disorders showed that inhibition of IL-13 could be therapeutically beneficial. 
The data on INF-γ and IL-10 secretion assays performed on CD4+ cells have shown a high 
individual variability and surely other studies have to be performed to further investigate the role 




These cytokines are particularly relevant since they may represent a redirection of the allergen-
specific Th2 response towards a protective Th1 immune response and establish an allergen-
specific immune tolerance [56, 121-122]. It is known that a wide range of cellular types produce 
IFN-γ and IL-10. Moreover, these cytokines regulate negatively the production of IL-5 and IL-13 
by CD4+ cells [108, 120]. 
In recent years, numerous studies about the mechanism of immune tolerance have been performed 
in order to define new therapeutic protocols for the prevention and the treatment of several 
diseases including the allergic inflammation. The pivotal role of Tregs in inducing and maintaining 
peripheral immune tolerance and more generally in the control of both innate and adaptive 
immune response has been demonstrated in several immune diseases [19, 28, 79, 145]. These cells 
are important in maintaining protection against tumors, viral infections, allergen inflammations 
and transplantations. Defects in their function can induce immunological disorders and therefore 
the possibility to study Treg function could have many therapeutic potential applications. Many 
studies have been carried out to characterize Treg phenotypes and biological activity. Recent 
evidences have shown that allergen specific immunotherapy is the only valid treatment that leads 
to the reversal of the allergic disease and to the induction of a long tolerance and restoration of the 
normal immune response to allergens [80]. The induction of T regulatory cells with a T regulatory 
phenotype seems to be a critical event in a successful allergen specific immunotherapy. These 
cells use several modes of immune regulation to achieve tolerance: cytokines mediated 
mechanisms, metabolic distruption, cell contact dependent mechanisms and cytolisis. 
In order to study the selection of an allergen-specific subset of Tregs, first PBMC of allergic 
patients were cultured with the mixture of wild type allergens or with the rPjEDcys hybrid, and 
were analyzed for the expression of CD25 on CD4+ cells. CD25 is expressed by Tregs and also by 
activated effector T cells, but the density of CD25 expression allows us to discriminate between 
these two T cell populations.  
Our analysis has shown that the CD25 antigen was upregulated on CD4+ cells after the in vitro 
stimulation with Parietaria major allergens and with the hypoallergenic derivative. Furthermore, 
hypoallergenic hybrid induced an increase the number of cells with high-density expression of 
CD25 higher than wild type allergens. Following this line of evidence, we sought to characterize 
the allergen-specific Treg activated after the in vitro stimulation. Nevertheless, the analysis based 
on the density of CD25 expression allowed us to discriminate between regulatory and activated 
effector T cells and other markers have been helpful in this discrimination. Moreover, only after 
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the in vitro stimulation with hypoallergenic hybrid, the Mean Fluorescence Intensity (MFI) of 
CD25 expression in CD4+ cells increased compared to an unstimulated culture. These results 
suggested the selection of a Treg subset in response to rPjEDcys. 
Therefore, in addition to high expression of CD4 and CD25, Treg cells were also characterized by 
low or not expression of CD127. Several papers have identified CD127 as an excellent marker of 
Treg cells in human peripheral blood. The cell surface marker is expressed at low levels on pTreg 
cells and distinguishes the CD4+ T cells as potential Treg cells. The demonstration of a selective 
increase of CD4+ CD25++ T cells that do not express CD127 provides an interesting result. It 
suggests the induction of a putative Treg subset.  
In these experimental settings, we were able to demonstrate that PBMC from Parietaria allergic 
patients stimulated with the wild type allergen and with hypoallergenic hybrid increased the 
percentage of CD4+CD25++ CD127- cells. Moreover, the rPjEDcys induced a more significative 
increase in the percentage of CD4+CD25++CD127- compared to the mixture of wild type allergens. 
In order to characterize these CD4+CD25++CD127- cells, these were isolated by magnetic 
separation using a two-step procedure. The enriched Treg fractions were purified and total RNA 
was extracted for a subsequent molecular characterization of enriched CD4+ CD25++ CD127- cells.  
We decided to study the level of mRNA expression of FoxP3, IL-10, GARP and TGF-β on the 
enriched CD4+ CD25++ CD127- cell fraction. Our analyses on FoxP3 and IL-10 mRNA levels 
showed that PBMC stimulation with mixture and rPjEDcys induced an increase in mRNA level 
expression. For the most part, except for one patient, the levels of FoxP3 and IL-10 mRNA were 
higher in response to rPjEDcys than the mixture. Our analyses on TGF-β did not show significant 
difference among the various samples. Instead, the RTq-PCR analyses on GARP showed very low 
levels and high variability within the same patient or between analyzed patients. The latter 
observation was confirmed by recently data published by Battaglia et al. which suggest the almost 
undetectable GARP mRNA expression in CD4+ T cells, meanwhile the kinetics of GARP 
expression varies depending on the subset of pTreg cells. Moreover it was suggested a post-
transcriptional regulation of GARP expression [35, 128]. In many Treg subsets the level of GARP 
mRNA increases during the first 6h and decrease at 24h. Moreover, some T helper clones could 
have high level of GARP mRNA, comparable to that of Tregs. A major limit in the study of Tregs 
is the absence of specific cell surface markers, but the discovery of potential markers for activated 
antigen-specific Tregs encouraged the study of these cells looking at the their function. 
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In line with these data, we decided to study GARP and LAP expression. Our results showed a 
rapid expression of GARP on CD4+ CD25++ cell surface 2-6h post-stimulation and a late 
expression 2 days post-stimulation in response to both antigens. On the other hand, studies on LAP 
expression showed an heterogeneous response to the mixture and PjEDcys in our population, 
showing a LAP increase at 2 or 4h followed by a downregulation to resting level 24 hours after 
stimulation or a second increase at 6 or 24 hours after stimulation (and 3 days after stimulation 
with hypoallergen). Moreover, using a multiparametric analysis we demonstrate the co-expression 
of both molecules on CD4+ CD25++ cell surface after PBMC stimulation with both the w.t. mixture 
and rPjEDcys. Although the main mechanism by which Tregs mediate immune suppression and 
promote tolerance is cytokine-mediated, Tregs employ multiple immunoregulatory mechanisms. 
Therefore we were interested to further characterize the selection of Treg subsets by studying other 
functional markers of Treg cells. A growing body of evidence supports an important role for the 
Treg activities mediated by CD39/CD73 adenosine pathway in regulating immune response. CD39 
(ENTPD1) and CD73 (ecto-5’-nucleotidase) are two cell surface ecto-enzymes that regulate levels 
of ATP and adenosine in extracellular microenvironment [132-133]. For these reasons, in order to 
study the activation of the adenosine pathway by allergen-specific pTreg cells, PBMC of allergic 
patients were cultured with the mixture of wild type allergens or with the rPjEDcys hybrid, and 
were analyzed for the expression of CD4 and CD39. Our analyses showed that PBMC in vitro 
stimulation with rPjEDcys induced a more significant increase in percentage of CD4+CD39+ cells 
compared to unstimulated sample and the mixture of wild type allergens. Recent data indicated a 
possible cross-talk between regulatory pathways; these suggested the connection between the 
TGF-β and the adenosine pathways, in both human and mouse immune system [132-133]. With the aim to investigate if this mechanism is also induced by PBMC stimulation with the 
mixture and rPjEDcys, we studied the co-expression of CD39 with GARP and LAP on CD4+ cells. 
In summary, our preliminary data demonstrated that rPjEDcys induced a more significant increase 
in percentage of CD4+ cells co-expressing CD39 and GARP or CD39 and LAP than those induced 
by wild type mixture of allergens.  
Finally, we started to study another functional marker of Tregs, as PD1, our data showed the 
modulation of PD1 in PBMC stimulated with the mixture and rPjEDcys. However, the percentage 
of CD4+ CD25++ PD1+ cells induced by PBMC stimulation with rPjEDcys is higher than those 
induced by allergens.  Moreover, the MFI of PD1 expression in these cells after the in vitro 




In conclusion, the collective studies performed during my PhD work have analyzed different 
immunological mechanisms involved in allergic responses to environmental allergens and 
associated with allergen specific immunotherapy.  
Our data suggested that the hypoallergenic hybrid, rPjEDcys expressing disulphide bond variants 
of Par j 1 and Par j 2, could be an improved tool for a new form of allergy vaccination, as: 
- It retains the immunogenicity, such the ability to induce both innate and adaptive immune 
response; 
- It shows a reduced allergenic activity, such reduction of the secretion of two Th2 cytokines 
that are critical in the development of allergy such as IL-5 and IL-13; 
- It appears to induce the selection of regulatory cell subsets which are characterized by the 
expression of functional markers as GARP, LAP, CD39 and PD1.  
Further investigations of these aspects will be useful to elucidate the mechanisms by which 
rPjEDcys may skew the immune system and consequently reduce the inflammatory allergic 
response. 
The knowledge of the basic mechanisms of allergic response may thus help the development of 
new therapies. Improvement in understanding and strategies for allergen specific immunotherapy 
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